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1INTRODUCTION
Epilepsy is an important public health problem and the second most common
neurological problem next to headache(1). In  worldwide and in India its prevalence is
about 50 million and 10 million persons respectively  according to WORLD HEALTH
ORGANISATION(2–4). It is defined as two or more episodes of unprovoked seizures
by ILAE(4). Epilepsy is the disorder of the brain characterised by a predisposition to
develop seizures. Antiepileptic medications remains the main line of treatment for a
patient with epilepsy. Antiepileptic medications can cause acute and chronic adverse
effects with greater impact on quality of life(5). Evidence suggest association between
AED’s and bone mineral abnormalities(6).Due to abnormalities in bone mineral
metabolism caused by these drugs , taking them for longer period of  time without
adequate supplementation imposes increased risk of fractures(7) and bone loss
(osteomalacia) thereby affecting the health and quality of life . The bone mineral
abnormalities commonly (8,9)observed are
o Hypocalcaemia,
o Hypophosphatemia,
o Increased PTH
o Increased Alkaline Phosphatase,
o Evidence Of Bone Loss On X- Ray.
o Decreased levels of active vitamin D metabolites
The drugs commonly associated with these risk are phenytoin, phenobarbitone,
carbamazepine and sodium valproate. These drugs are potent inducers of
CYTOCHROME P 450(10–13). The induction of these enzymes leads to conversion
2of vitamin D into inactive metabolites thereby decreasing vitamin D mediated
intestinal calcium absorption.
Other  possible mechanisms for affecting bone health are
o Direct Inhibition Of Intestinal Calcium Absorption
o End Organ Resistance To Vitamin D And PTH.
Studies have been reported from 1960’s by KRUSE ET AL(14), RICHEN
AND ROWE ET AL(15), DENT ET AL(16), etc about the effects of the
antiepileptic medications on bone health and mineral homeostasis. In various national
and international studies being reported for the past four decades, the prevalence of
hypocalcemia was estimated to be 3 to 30%(17) and that of increased alkaline
phosphatase was 27 to 41 %(18) which is a marker of increased bone turnover caused
by bone loss. The hypocalcemia will lead to secondary hyperparathyroidism. The
severity of these abnormalities is determined by the duration of therapy and number of
drugs taken.
Hypocalcaemia is defined as the serum calcium levels less than 8.5 mg/dl and
alkaline phosphatase levels more than 140 IU/L is considered high. Since the problem
is subclinical , patients are unaware about the bone loss and their increased risk for
fractures.
So studies have proved that supplementing these patients with calcium and
vitamin D analogs will reduce the risk of fractures and bone loss by enduring adequate
strength to bone and by maintaining mineral homeostasis.(19)
Our study focuses  about comparing  the levels of calcium and alkaline
phosphatase  in patients on  antiepileptics and those not on antiepileptics in an
3outpatient basis  and also to assess  the prevalence of hypocalcemia among patients on
antiepileptic therapy. The data obtained from the study will help us to determine the
need for calcium and vitamin D supplementation in patients on chronic antiepileptic
therapy to avoid the risk of fractures and monitor them periodically with the help of
these markers of bone health to avoid the complications.
4REVIEW OF LITERATURE
Epilepsy is an important public health problem with more than 50 million
people affected by the disease throughout the world(2).  It is the second most common
neurological condition that stands next to headache.(1) This  disorder necessitates the
patients to be on antiepileptic  therapy that includes enzyme inducing (phenytoin,
phenobarbitone, carbamazepine) and non enzyme inducing drugs. The treatment with
antiepileptic agents is often chronic. AED’s can cause acute and chronic adverse
effects that can affect the quality of people’s life. The longer duration of therapy is
associated with abnormalities of bone ranging from decrease in mineral metabolism of
bone to decrease in bone mineral density and fracture risk(6). Their fracture risk is
increased by 2 to 6 times compared to general population(7).
Although studies have been reported about the risk of bone disease in patients
on antiepileptic therapy in institutionalised patients due to lack of nutrition and factors
like sunlight exposure, in the past four decades, articles about the risk of it in
ambulatory patients has also been(20) published.
In the year 1968 in  a study conducted by KRUSE(14), he has  reported
abnormalities in the levels of calcium, alkaline phosphatase and phosphate , with X
ray evidence of osteomalcia in about 15% of children taking antiepileptic therapy. The
severity of the disease is determined by the number of drugs taken and duration of the
therapy(15).
In a study conducted by Petty et al(21), prevalence of clinical or subclinical
bone disorders was more than 50% in patients on chronic antiepileptic medications.
5The common abnormalities  observed with antiepileptic therapies are:
1. Hypocalcemia.
2. Increased alkaline phosphatase.
3. Increased parathyroid hormone.
4. Hypophosphatemia.
5. Reduced levels of biologically active vitamin D metabolites.
6. Radiologic evidence of rickets .
7. Histologic evidence of osteomalacia.
Enzyme inducing antiepileptic drugs like phenytoin, phenobarbitone,
carbamazepine, primodine are known to cause these side effects.
PREVALANCE OF EPILEPSY WORLDWIDE:
The prevalence of epilepsy in the world is estimated to be 50 million
worldwide at any given time(4). Prevalence and incidence of epilepsy differs by
demographic factors like age, race, sex and socioeconomic status. In developing
countries,the likelihood of epilepsy is more in adolescence and adults. In developed
countries it increases as age increases. With relation to sex, males are reported to be
more than females (1)because females tend to conceal their symptoms and diagnosis
due to beliefs. Prevalence of epilepsy is more in people with low socioeconomic status
because of poor health conditions.
6EPILEPSY IN INDIA:
According to world health organisation, About 10 million persons with
epilepsy  are estimated to be present in India with a prevalence ofabout 1%. In
Bangalore Urban Rural Neuro Epidemiological Survey (BURNS), it was observed
in various studies  that the prevalence rate  of epilepsy was 5 to 10/1000 population,
among which rate in rural areas is higher than that in urban areas. In a study
conducted by BHARUCHA et al(22), males are significantly higher than females
according to the prevalence rates.
DEFINITION OF EPILEPSY:
Defined as a condition characterised by two or more episodes of  seizures due
to unprovoked causes  according to INTERNATIONAL LEAGUE AGAINST
EPILEPSY (ILAE 1993).
The term  seizure, a latin word ( meaning - to take possession of ) is a sudden
unexpected event due to abnormal neuronal  activity in  the brain.  It is manifested as
episodes ranging from events indistinguishable by the observer to  obvious convulsive
activity. It can be provoked ( due to underlying structural or metabolic causes ) or
unprovoked.
CLASSIFICATION OF SEIZURES :
Based on electrical and clinical activities seizures are classified into 2 major
types:
 FOCAL
 GENERALISED
7• FOCAL - arises in certain areas within cerebral hemispheres and limited to
the same. Mostly due to structural problems in the  brain.
• GENERALISED: arises within and spreads rapidly across cerebral
hemispheres.  Mostly due to cellular, biochemical or structural causes.
SUBCLASSIFICATION:
Focal seizures
(Can be further described as having motor, sensory, autonomic, cognitive or
other features ).
Generalized seizures
a. Absence – typical and antitypical
b. Tonic
c. Clonic
d. Tonic - clonic
e. Atonic
f. Myoclonic
• May be focal, generalized, or unclear
Epileptic spasms.
CAUSES OF SEIZURES:
Seizures occurs as a result of loss of balance between excitation and inhibition
in the CNS. Clinical observations have stressed that various factors influence
conditions that can cause seizures or epilepsy
81. Certain endogenous factors can determine the development of seizures in
appropriate situations by reducing its threshold. Ex: febrile seizures.
2. EPILEPTOGENIC FACTORS - which converts the normal neurons of the
brain into hyperexcitable ones. Some  of them are infections, trauma, stroke,
developmental anomalies,etc..
3. PRECIPITATING FACTORS: certain factors can precipitate seizures in
epileptic or non epileptic.  Like deprived sleep, stress, toxin or drug exposure.
ANTIEPILEPTIC THERAPY:
Patients diagnosed with epilepsy are started on antiepileptic therapy
irrespective of the cause. It is the mainstay of treatment for all patients in controlling
the further episodes of the seizures. Duration of treatment with these drugs are usually
for chronic period of time and this imposes the patient on risk for fractures, bone loss
due to abnormalities in the bone mineral metabolism(6,7). The risk for bone loss is
determined by the duration of therapy and number of drugs taken. Studies have been
reported that the bone loss begins within 3 to 6 months of starting the therapy(19).
The antiepileptic drugs encompasses a variety of drugs with different
mechanism of actions. Among the antiepileptics used, some are potent inducers of
cytochrome P - 450 enzymes and some of them are inhibitors of it. First line drugs
like phenytoin, phenobarbitone, carbamazepine and primidone are potent inducers and
sodium valproate is an inhibitor.
9New generation drugs like topiramate, levecetiracetam,zonisamide,lamotrigine
(23)etc are not enzyme inducers and thus are not associated with abnormalities of
mineral metabolism.
In India, phenytoin, phenobarbitone, sodium valproate and carbamazepine are
the first line  and commonly used drugs in government hospitals.
MECHANISM OF ACTION :
PHENYTOIN:
• It limits the spread of seizure activity with maximum effect on tonic phase
of convulsive seizures.
• It stabilises the neuronal membrane and prevents repetitive detonation by
prolonging the inactivated state of voltage sensitive neuronal Na+ channel.
• Inhibits high frequency discharges.
• Other mechanism – inhibition of glutamate, reduction of calcium influx
• Dosage - 300 to 400 mg/ day
• Metabolised by CYP2C9
• Side effects:
1. Gum hypertrophy, Megaloblastic Anaemia
2. Osteomalacia
3. Hirsutism
4. Skin rash and Lymphadenopathy
5. Neurologic – dizziness diplopia, incoordination
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• CARBAMAZEPINE:It acts  by prolonging the inactivated state of neuronal
Na+channel.
• Metabolised by CYP2CP and potent inducer of CYP3A4
• DOSE – 600 to 1800 mg/day
• Side effects
1. Ataxia
2. Aplastic anaemia and Leucopenia
3. Gastrointestinal irritation, Obstructive Jaundice
4. Hyponatremia
5. Osteomalcia
PHENOBARBITONE:
• Acts by enhancement of GABA mediated synaptic inhibition
• Dose – 60 to 180 mg/day
• Side effects:
1. Sedation
2. Ataxia
3. Confusion
4. Skin rash
5. Osteomalacia
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FIG 1 – Showing  Development of osteoblasts and osteoclasts from bone marrow
progenitors and factors affecting it. PTH: Parathyroid Hormone, GH – Growth
Hormone, IGF – Insulin Like Growth Factor
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BONE STRUCTURE AND METABOLISM:
Bone is a modified dynamic tissue that is continuously remodelled throughout life.
Bone is made up of three types of  specialised cells:
Osteoblasts – that initiates bone formation
Osteocytes – monitors bone progress
Osteoclasts – initiates bone reabsorption
BONE MATRIX:
 Inorganic – constitutes bone minerals.
60 to 70% of bone weight.
Formed by calcium and phosphorus predominantly.
 Organic – includes collagenous and non collagenous matrix.
 Collagenous
forms 30% of dry bone weight.
Made of type 1 collagen (90%) and small amount by type 4 collagen.
 Noncollagenous -
Includes osteopontin, calcium binding proteins like matrix glaprotein and
osteocalcin, thrombospondin, bone specific alkaline phosphatase, bone morphogenetic
protein.
The functions of the osteoblasts are controlled by a variety of minerals like
calcium, phosphorus and hormones like Insulin like growth factor 1 and 2, PTH,
vitamin D3.
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BIOCHEMICAL MARKERS FOR BONE REMODELLING :
• Divided into makers of bone formation mediated by osteoblasts and markers of
bone resorption which represents osteoclastic activity.
• Osteoblast activity is reflected by increased levels of alkaline phosphatase,
type I procollagen C-terminal peptide (PICP) and osteocalcin which serves as
markers of bone formation.
• Bone resorption markers are urinary hydroxyproline, hydroxylysine.
• Alkaline phosphatase is the most common marker for bone formation although
it is present as two isoenzymes, bone and liver.
• Physiologically bone markers are elevated during growing age and bone
repairs.
REGULATION OF BONE REMODELLING:
• Regulated by minerals like calcium and phosphorus and hormones like
Vitamin D3, PTH, Insulin like growth factor 1and 2, sex hormones.
• To some extent ,nutrition and physical activity also influences remodelling.
• Medications like steroids , AED’s and decreased estrogen in postmenopausal
women are likely to induce bone loss, there by increasing risk of fractures.
EPILEPSY AND BONE:
Patients with epilepsy are prone for fractures due to various factors like use of
AED’s causing bone loss, falls during seizure activity and ataxia, giddiness and
sedation caused by antiepileptic drugs can increase the risk of fracture.(24–26)
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ANTIEPILEPTICS AND FACTORS AFFECTING BONE REMODELLING:
Adverse effects on bone by AED’s is being reported from past four decades. It
includes abnormalities like hypocalcemia , low vitamin D levels, increased PTH and
low phosphate levels(27). These abnormalities are commonly found with enzyme
inducing antiepileptics like PHT, CBZ, PB. These antiepilpetics produce these
abnormalities by increasing the catabolism of vitamin D into inactive metabolites and
also by affecting the cellular response to PTH. These above mechanisms has been
proposed to increase bone turnover and to increase remodelling of bone. In addition
PHT, also affects the direct intestinal calcium absorption and vitamin D mediated
calcium absorption to some extent(27). Some of the studies showed no significant
differences in calcium and phosphate levels in patients in chronic AED’S(28,29).
Sodium valproate being an enzyme inhibitor is known to affect the bone mineral
metabolism by stimulating the osteoclast activity(30).
Increased levels of PTH has been reported in epileptic patients on chronic
AED’S. This increase in PTH is likely to be a secondary response to low vitamin D
levels.(11) However , studies  reporting  increased PTH levels without  associated
decrease in vitamin D levels has been published thereby suggesting mechanisms
independent of vitamin D deficiency affecting bone metabolism by antiepileptics.
High PTH levels increases the bone turnover and predisposes to decreased bone loss
and osteomalacia.
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Drugs like phenytoin and CBZ are known to induce osteomalacia by inhibiting
the profileration of human osteoblast cells besides affecting calcium and vitamin D
homeostasis.
Studies have reported low levels of active vitamin D metabolites in patients on
chronic antiepileptic therapy due to induction of hepatic enzymes by enzyme inducing
drugs like PHT,CBZ, PB(10–13)
ANTIEPILEPTICS AND BONE DENSITY:
A decrease in bone mineral density and secondary osteoporosis was observed
in patients using AED’S(17). Bones commonly affected are the femur and lumbar
vertebrae. The risk for osteoporosis is 1.7 to 3.8, for osteopenia 1.3 to 3.8 and
fractures it is 1.7 to 6.1(31). The sequence is normal BMD to osteopenia to
osteoporosis to fractures.
The risk factors for reduced BMD in epileptic patients are as follows:
• Reduced physical activity
• Lack of sunlight exposure
• Inadequate dietary intake of calcium
• Postmenopausal women
• Alcohol and smoking
• Concomitant intake of drugs like glucocorticoids, chemotherapy.
• Female gender.
• Intestinal malabsorption and liver diseases.
• Hyperthyroidism and hyperparathyroidism(32)
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A study by KULAK ET AL(28) has reported 53.4% and 10.4% of osteopenia
and osteoporosis respectively. These observations are common with enzyme inducing
AED’S and for enzyme inhibitor like sodium valproate. In a few small studies new
antiepileptics are also associated with bone loss.
ANTIEPILEPTICS AND BONE TURNOVER:
Studies have demonstrated increase in markers of bone remodelling with the
use of antiepileptics more with enzyme inducing AED’s(33–37) The markers are
as follows:
BONE FORMATION MARKERS – like osteocalcin, PICP, total and bone specific
alkaline phosphatase.
BONE RESORPTION MARKERS – like N-telopeptide of type I collagen (NTX) and
carboxy-terminal telopeptide of type I collagen (ICTP) andurinary
deoxypyridinolines.
The increased levels of these markers is associated with decrease in bone mass
which is a contributing mechanism for fracture risk. Histological evidence has
suggested that the bone disease is mainly due to increased bone turnover (38).
ANTIEPILEPTICS ASSOCIATED WITH BONE DISEASE:
The antiepileptics most commonly associated with bone mineral abnormalities
are cytochrome enzyme inducing drugs like PHENYTOIN, PHENOBARBITONE,
CARBAMAZEPINE, PRIMIDONE. Majority of the studies that has got published till
date is about these medications.
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Studies regarding enzyme inhibiting drug like sodium valproate is limited.
But in a study conducted in patients taking long term valproate therapy found
increased concentrations of serum calcium, low Vitamin D3 concentrations,reduced
bone mineral density using DEXA scan and increased markers of bone resorption.
Newer antiepileptic drugs like lamotrigine, topiramate. Zonisamide etc.. are
less likely to cause these abnormalities as they are not potent enzyme inducers.
Studies with no clinical significance regarding these abnormalities have come up in
past few years.
Polytherapy is associated with more abnormalities than single therapy. No
single combination is proved to be significant in causing more disease.
MECHANISM OF BONE LOSS BY ANTIEPILEPTICS:
Studies have been reported about the effects of enzyme inducing antiepileptic
drugs on bone mineral metabolism and bone loss from 1960’s. Since then evidence of
AED’s causing metabolic, biochemical and radiological abnormalities has  been
reported . Enzyme inducing AED’s may lead to catabolism of vitamin D and
hypocalcemia .  Several mechanisms have been postulated which are listed below :
 Alteration of calcium metabolism :
 Reduced  Intestinal Cation transport
 Vitamin D mediated calcium absorption reduced
 Intestinal calcium absorption decreased
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 Vitamin D Inactivation :
• Induction of Hepatic enzyme
• Pregnane  X Receptor activation
 Osteoblast inhibition
 Decreased calcitonin
 Vitamin K deficiency
 Altered sex steroid and SHBG metabolism
 Modulation of aromatase activity
 Increased parathyroid hormone:
• Insufficiency of vitamin D
• Reduced cellular response to parathyroid hormone
Several theories has been published about the possible mechanisms of AED’s
induced bone loss. Among that induction of hepatic enzymes leading to conversion of
vitamin D into inactive polar metabolites is the principal mechanism. But for drugs
like sodium valproate which is an inhibitor of hepatic microsomes this mechanism
will not explain the findings.
AED’S AND CALCIUM:
• It is postulated that enzyme inducing antiepileptic drugs like phenytoin,
phenobarbitone, carbamazepine induces CYTOCHROME P450 which leads to
catabolism of vitamin D into inactive polar metabolites thereby reducing
biologically active vitamin D.
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• Low levels of vitamin D causes hypocalcemia  and hypophosphatemia due to
decreased intestinal absorption  and also increases the levels of parathyroid
hormone leading to secondary hyperparathyroidism. PTH increases
mobilisation of bone calcium stores and subsequent bone turnover. All these
abnormalities leads to bone loss thereby increasing the risk of fractures.
• AED’s especially PHENYTOIN may interfere with direct intestinal absorption
of CALCIUM by mechanisms not clearly defined when tested in rats. In a
study conducted by BORSTEL SMITH ET(39) published in the year 2007,
effect of phenytoin on calcium transport in CaCO2 cells has been studied.
AED’S AND PXR:
• Pregnane X receptor shares homology in their DNA binding domain with
vitamin D receptor . The PXR is expressed in intestine, kidney and bone.
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The figure 2 depicts the effects of PXR on vitamin D metabolism
PXR – Pregnane X Receptor, DPH – diphenylhydantoin , PB – phenobarbitone,
CBZ- carbamazepine.
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• Drugs like phenytoin, phenobarbitone and carbamazepine are activators of
PXR.
• Activation of PXR induces CYP 24 enzyme,  that directs side chain oxidation
and cleaves vitamin D3 into inactive metabolites thereby reducing active
cellular concentrations of vitamin D inducing bone loss.(40,41)
• PXR also affects the osteoblast growth thereby affecting bone health apart
from inactivating Vitamin D .
AED’S AND AROMATASE:
• Aromatase is an enzyme that functions in converting  adrenal androgens to
estrogens in peripheral tissues thereby maintaining the bone mineral
density(42).
• Evidence from studies suggest positive correlation between BMD and estrone
levels(42,43). So the above conversion by aromatase enzyme is essential.
• Aromatase is expressed in tissues like bone, liver , skin and gonadal tissues .
Vitamin D3 is an important regulator of the enzyme and physiological
concentrations  of vitamin D3 is essential to maintain the aromatase activity
in osteoblasts(42).
• AED’s by decreasing the active Vitamin D3 metabolites are known affect the
aromatase activity.
AED’S AND SEX HORMONES:
• Hepatic enzyme inducing AED’s are known to increase the catabolism of sex
steroids and increase the synthesis of sex hormone binding globulin {SHBG}.
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• AED’s especially CBZ, VPA , PHT are reported to inhibit synthesis of
testosterone from Leydig cells of testis(44)
• PHT and CBZ increases the levels of sex hormone binding globulin by
increasing its synthesis, thereby reducing the levels of sex hormones like
testosterone, DHEA and estrone.(45,46)
• PHT, CBZ and PB are known to increase the clearance of circulating
androgens(45).
• All the above changes reduces the activity of aromatase enzyme by
decreasing its androgen substrates and accelerates bone loss.(46–49)
AED’S AND VITAMIN K :
• Vitamin K is involved in posttranslational carboxylation of bone matrix
proteins like osteocalcin(27). Phenytoin induced vitamin K deficiency
causes bone loss by preventing the post translational modification. (9)
AED’S AND CALCITONIN:
• AED’s are known to cause calcitonin deficiency. Calcitonin is a hormone
produced by thyroid gland that inhibits osteoclast mediated bone
resorption. Calcitonin deficiency therefore accelerates bone loss.
AED’S AND BONE CELLS:
• PHT and CBZ  is  reported  to inhibit  the   profileration of human
osteoblast like cell(50) and VPA is reported to act by stimulating osteoclast
activity. PHT is shown to inhibit osteocalcin secretion from osteoblast(51).
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Table 1-Bio chemical abnormalities of bone metabolism associated with AED’S:
FEATURES LEVELS IN SERUM/URINE
CALCIUM REDUCED IN THE SERUM
PHOSPHATE REDUCED IN THE SERUM
25(OH)D3 REDUCED IN THE SERUM
PARATHYROID HORMONE ELEVATED IN THE SERUM
MARKERS OF BONE FORMATION
ELEVATED IN THE SERUM
MARKERS OF BONE RESORPTION
ELEVATED IN THE
SERUM/URINE
These are the postulated mechanisms by which AED’S are known to
cause abnormalities of bone mineral metabolism and thereby increases the
fracture risk.
24
The figure No: 3, depicts the effects of antiepileptic drugs on the bone mineral
metabolism
25
PREVALENCE OF HYPOCALCEMIA IN PATIENTS ON AED’S:
The purpose of my study was to assess the prevalence of hypocalcemia in
patients on antiepileptic therapy especially enzyme inducing AED’S. Various studies
have reported the prevalence to be in the range of 3 to 30%. The calcium levels were
in the subnormal levels not significant to cause symptoms.Studies have proved thatthe
severity of hypocalcemia increases as the duration of therapyand number of drugs
increases.(15,18)
CALCIUM AND BONE HOMEOSTASIS :
About 99% of calcium present in the human  body is stored in the skeleton
where it provides mechanical stability  to the bone and serves as reservoir for
maintaining extracellular calcium concentration at times..
Normal serum calcium level is 8.5 to 10.5 mg/dl .
FORMS OF CALCIUM AND ITS FUNCTION:
It is present  in two forms in the blood –
Ionised (50% of total calcium)
Non Ionised.
The ionised form is bound to negatively charged proteins like albumin,
immunoglobulin, phosphate, citrate, sulfate, or other anions.
FUNCTIONS OF IONISED CALCIUM: .
i. Neuromuscular activity by helping in transmission of impulses
ii. Secretion of Hormones,
iii. Cardiac Contractility, and
iv. Coagulation of Blood.
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ABSORPTION  OF CALCIUM:
The daily requirement of calcium as suggested by institute of medicine is 1000
to 1200 mg for adults . The ingested calcium is absorbed mainly in the duodenum and
proximal jejunum via active and passive transport. Passive (paracellular) transport is
nonsaturable and contributes to 5% of daily calcium intake. Active transport is via ion
channels TRPV5 and TRPV6, the expression of these ion channels is controlled by
1,25 (OH)2D. This form of absorption ranges from 20% to 70%.
REABSORPTION:
About   8 to 10g/d of calcium is filtered by the glomeruli. Of this,  65% is
reabsorbed in proximal tubules via passive transport.
20% is reabsorbed in the cortical thick ascending loop of henle with the help of
paracellin – 1. This reabsorption is inhibited by increased concentrations of calcium
via calcium sensing receptor independent of parathyroid hormone or active vitamin D
.  Finally, 10% is reabsorbed in the distal convoluted tubule. The calcium enters the
luminal surface of the cell via TRPV5. Ca- ATPases and Na+/ Ca2+ exchangers help
in pushing the calcium across the basolateral surface. All  these process are stimulated
directly or indirectly by PTH and vitamin D.
REGULATION
The extracellular Calcium concentrations are maintained  in the serum within a
narrow range  by the effects of parathyroid hormone, vitamin D and calcitonin.
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 PARATHYROID HORMONE:
It is a 84 amino acid single chain peptide. Secreted by four parathyroid glands
located on the posterior surface of the thyroid gland.
It is the principal regulator of extracellular calcium concentration in the blood.
It acts directly on the bone and kidney and indirectly in the intestine via vitamin D to
increase the calcium concentration in low states.  Calcium acting through the calcium
sensing receptor and vitamin D acting through the nuclear receptor regulates PTH
synthesis and secretion.
ACTIONS OF PTH:
o BONE : stimulates both  the  osteoclasts and the osteoblasts . Stimulation of
the  osteoclasts results in bone demineralisation thereby increasing the calcium
levels. Stimulation of osteoclast is indirect mediated by the cytokines released
by the activated osteoblasts, because they lack receptors for PTH. Stimulation
of the osteoblast will increase the bone remodelling. Hence , pulsatile secretion
of parathormone increases bone remodelling through osteoblasts whereas
sustained secretion will increase bone demineralisation through osteoclast
activation.
o KIDNEY – decreases the renal clearance of calcium
o INTESTINE- increases calcium absorption in the intestine through the
production of 1,25(OH)2D.
 VITAMIN D:
Vitamin D3 is the major steroid hormone involved in mineral ion homeostasis.
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SYNTHESIS AND METABOLISM:
Vitamin D is synthesised subcutaneously from 7- dehydrocholesterol and is
absorbed from intestine , bound to an alpha binding protein in the blood and taken to
liver.
In the liver, it is first hydroxylated by the cytochrome oxygenases to 25
hydroxy vitamin D, major storage and circulating form of the hormone.
In the bound form, it is taken to kidney where again it is hydroxylated by
cytochrome 25 hydroxyvitamin D 1 alpha hydroxylase in the proximal convoluted
tubules to 1,25,(OH)2 D. Finally 1,25,(OH)2 D undergoes hydroxylation into inactive
metabolites by the enzyme vitamin D 24 hydroxylase.
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Figure No 4, showing vitamin D synthesis in the body.
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Active metablolites of vitamin D that  are secreted into bile are reabsorbed by
enterohepatic circulation.
PTH and hypophosphatemia are inducers of the enzyme 25 hydroxyvitamin D
1 alpha hydroxylase whereas calcium , FGF23, 1,25,(OH)2D will suppress it.
SOURCES OF VITAMIN D:
Fortified cereals, diary products, egg yolks, fish oils.
Daily requirement - 600 IU
ACTIONS OF 1,25,(OH)2 D:
It mediates its effect by binding to VITAMIN D RECEPTOR,  which is a member
of  nuclear receptor family.
o INTESTINE:
• It increases the expression of TRPV5 and TRPV6 which are major
calcium transporters in the intestine.
• It stimulates calbindin 9K, calcium binding protein in the intestine, which
has a role in the calcium transport along the enterocyte.
o BONE:
Increases resorption of bone by increasing the expression of RANK
ligand and stimulating osteoclast activity.
Increases the expression of bone matrix proteins like osteopontin and
osteocalcin and type 1 collagen.
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CAUSES OF IMPAIRED VITAMIN D ACTION:
1. VITAMIN D DEFICIENCY:
i. Defective cutaneous production
ii. Deficient dietary intake
iii. Malabsorption
2. INCREASED LOSS OF VITAMIN:
i. Increased metabolism (phenytoin)
ii. Enterohepatic circulation impairment
iii. Nephrotic syndrome
3. IMPAIRED 25 HYDROXYLATION due to liver diseases.
4. IMPAIRED 1 ALPHA HYDROXYLATION:
i. Hypoparathyroidism
ii. Renal failure
iii. 1 alpha hydroxylase mutation
5. END ORGAN RESISTANCE :
i. VDR mutation
ii. Phenytoin
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Figure No. 5, Showing Effects Of Vitamin D In Body
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CLINICAL MANIFESTATIONS OF VITAMIN D DEFICIENCY:
Manifestations  are largely due to defective intestinal calcium absorption.
Deficiency for longer duration may cause hypocalcemia , osteomalacia, myopathy.
DIAGNOSIS OF VITAMIN D DEFICIENCY:
Most specific screening test for vitamin D deficiency is serum 25(OH)D level.
Levels more than 20 ng/ml is considered adequate.
Metabolic abnormalities:
1. Low calcium ( both ionised and total)
2. Low phosphorus
3. Increased PTH.
4. Increased alkaline phosphatase levels due to PTH mediated increased bone
turnover.
HYPOCALCEMIA:
Defined as total calcium levels less than 8.5mg/dl with normal serum albumin
or ionised calcium less than 4.2 mg/dl.
In the setting of hypoalbuminemia which can falsely lower total calcium levels,
corrected calcium levels are measured using the formula given below:
CORRECTED Ca2++ = (Ca++)+[0.8X(4.0-ALBUMIN)]
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FIG NO: 6 FLOW CHART SHOWING EFFECTS OF LOW CALCIUM AND
ITS EFFECTS.
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CAUSES OF HYPOCALCEMIA:
Can be due to absent PTH , overproduction or ineffectiveness
LOW PTH LEVELS:
1. Hereditary hypoparathyroidism – due to agenesis
2. Acquired hypoparathyroidism
i. Surgery
ii. Radiation
iii. Infiltration
iv. Tumor
3. Hypomagnesemia
INEFFECTIVE PTH:
1. Renal disease with impaired production of vitamin D.
2. Nutritional deficiency.
3. Resistance to vitamin D.
4. PTH resistance syndromes including pseudohypoparathyroidism.
5. Altered  vitamin D metabolism ( phenytoin)
OTHER CAUSES:
1. Acute pancreatitis
2. Tumor lysis syndrome
3. Severe hyperphosphatemia
4. Drugs – bisphosphonates, heparin, protamine sulfate
5. Hungry bone syndrome after parathyroidectomy
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CLINICAL MANIFESTATIONS OF HYPOCALCEMIA:
Depends on the degree of hypocalcemia and rate of onset
o Mild and chronic hypocalcemia is usually asymptomatic.
o Acute moderate – leads to circumoral  or distal paresthesias and tetany.
o Acute severe - leads to larynospasm, confusion, seizures , vascular
collapse with bradycardia and decompensated heart failure.
SIGNS:
TROUSSEAU’S SIGN - inflating the BP cuff  20 mm Hg above SBP for 3 minutes
leads to development of carpopedal spasm.
CHVOSTEK SIGN- facial muscle twitching when the nerve is trapped anterior to
the ear.
APPROACH AND INVESTIGATIONS:
 History of any systemic diseases and drugs that can cause low calcium levels
 Physical examination for any neck surgery
 Investigations
i. Serum albumin to rule out hypoalbuminemia
ii. Serum parathyroid hormone levels
iii. Serum phosphorus
iv. 25(OH) vitamin levels
v. Serum magnesium
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MANAGEMENT OF ANTIEPILEPTIC INDUCED BONE LOSS:
Management involves
1. discussing the risk of bone loss and its complications to patients on chronic
antiepileptic drugs,
2. to discuss about the risk factors known to aggravate the bone loss and to avoid
it
3. to identify high risk patients prior to treatment  and evaluate them.
High risk patients includes
• Institutionalized And Non-Ambulatory Subjects
• Increased Duration Of Treatment And Multiple Number Of Drugs
• Poor Sunlight Exposure
• Inadequate Dietary Intake
• Postmenopausal women
• Hypothyroid patients
• Smokers and alcoholics
• Concomitant steroid intake
• Chronic treatment and increased drugs
4. regular screening for blood biochemical markers and bone density
5. encourage to adopt regular weight bearing exercises, adequate exposure to
sunlight and increase the intake of essential nutrients like calcium, phosphorus,
vitamin D.
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MONITORING:
No clear recommendations have come up for the monitoring of patients with
chronic enzyme inducing antiepileptic agents. Suggestions are:
• Monitoring of calcium, phosphorus, vitamin D  and PTH before start
of the treatment and then at 6 months interval.
• DEXA screening:
• For postmenopausal women on AED’s, DEXA is recommended
before start of treatment and then at yearly intervals.
• Subjects with one risk factor for osteoporosis should be monitored
every 2nd year.
• Subjects with no risk for osteoporosis should be monitored once in  5
years.
• Endocrinologists opinion should be seeked if biochemical parameters
are low and DEXA and BMD are low
CALCIUM AND VITAMIN D SUPPLEMENTATION:
The recommended daily requirement of calcium is 400 to 800mg/d and that of
vitamin D is 400 IU/D. Patients on antiepileptic therapy should be supplemented with
high doses of calcium ( 1000 to 1500 mg/d ) and vitamin D (4000IU/D) because even
healthy adults are deficient in vitamin D in India. Studies has been published about the
effects of low dose and high dose Vitamin D. After a treatment of one year, BMD is
found to be increased and fracture risk has been decreased. In a study conducted by
PATICIO et al, fracture has been reduced by 2% in patients on calcium and vitamin D
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supplementation. In a study conducted by Krishnamoorthy et al, it has been observed
that simultaneous supplementation with calcium and vitamin D has not led to changes
in biochemical parameters. Oral bisphosphonates has been tried in preventing
osteoporosis.
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OBJECTIVES OF THE STUDY
a. To compare and study the levels of calcium and alkaline phosphatase as
markers of bone health in patients on antiepileptic therapy and normal
patients
b. To assess prevalence of hypocalcemia in patients on antiepileptic
therapy.
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MATERIALS AND METHODS
STUDY DESIGN - CASE CONTROL STUDY
STUDY PERIOD – October 2017 to August 2018
STUDY POPULATION :
This study was conducted in a outpatient basis in Government Vellore Medical
College Hospital among 200 cases who were epileptic patients on antiepileptic drugs
and 200 controls who were patients visiting the OP for medical ailments other than
epilepsy.
INCLUSION CRITERIA FOR CASES:
1. All epileptic patients of both sexes on antiepileptic therapy
2. Duration of treatment more than 1 year
3. Age – 16 to 50 years
INCLUSION CRITERIA FOR CONTROLS :
1. Non epileptic patients of both sexes.
2. Age – 16 to 50 years
EXCLUSION CRITERIA FOR CASES AND CONTROLS:
1. Patients denying consent
2. Disease known to cause decrease in calcium and increase in alkaline
phosphatase levels
3. Drugs causing Hypocalcemia.
4. History of jaundice in the past
5. History of alcohol intake
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6. Postmenopausal Women
7. Patients on Calcium And Vitamin D Supplementation
8. Patients with History Of Liver And Renal Diseases
9. Patients on Antitubercular Drugs
DATA COLLECTION :
AFTER obtaining informed consent, detailed history was taken and blood
sample taken and sent for investigation and the datas were entered in the proforma
designed for the study.
LABORATORY INVESTIGATIONS:
1. SERUM CALCIUM
2. SERUM ALBUMIN
3. RENAL FUNCTION TEST – UREA AND CREATININE
4. SERUM ALKALINE PHOSPHATASE LEVELS
5. SGOT AND SGPT LEVELS
COLLABORATING DEPARTMENTS:
DEPARTMENT OF NEUROLOGY
DEPARTMENT OF BIOCHEMISTRY
EPILEPSY is defined as condition characterised by two or more episodes of
unprovoked seizures. The patients started on antiepileptic drugs for the condition are
prone to develop metabolic bone disease due to decreased calcium levels due to
enzyme inducing properties of the antiepileptic drugs like phenytoin, phenobarbitone,
carbamazepine and sodium valproate. Also the levels of serum alkaline phosphatase
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levels are increased due to increased bone turnover caused by bone loss. Patients
meeting the criteria for study were included. Patients were informed about the study
and those accepting to proceed was included after getting informed consent. The
presence or absence of the following data was recorded for all the patients in a data
extraction proforma –
1. Age and Sex of the patient
2. Occupation
3. History of neck Surgery
4. History of acute abdomen in the past
5. History of radiation in the neck
6. History of jaundice
7. History of alcohol consumption
8. Presence of renal or liver diseases
9. Antitubercular drugs history
10. Hypertension or diabetes mellitus
11. Duration of treatment for epilepsy
12. Type of therapy – Monotherapy Or Dual Therapy Or Triple
Therapy
13. Name of the drug taken
History of neck surgery:
History of surgery in the neck especially thyroid surgery or any
other neck surgeries are prone to damage the parathyroid gland leading to low
parathormone levels and thereby reducing calcium levels in the body.
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History of acute abdomen in the past :
Conditions like acute and chronic pancreatitis are known to cause decrease in
the calcium levels . Hypocalcemia is one of the component of Ranson Score used for
assessing acute pancreatitis. Some possible mechanisms for hypocalcemia are
formation of calcium salts, sepsis induced hypocalcemia, hypomagnesaemia induced
impaired PTH secretion and action, relative PTH deficiency and vitamin D deficiency
History of radiation to the neck:
As like neck surgery, radiation to the neck for some malignancy may damage
the parathyroid gland causing hypocalcemia.
Jaundice in the past:
Obstructive causes of jaundice is known to elevate alkaline phosphatase levels
Alcohol consumption:
Chronic alcoholism leads to hypocalcemia. Possible mechasims include
magnesium depletion , impaired PTH release and action, decreased renal tubular
absorption of calcium.
Presence of diabetes mellitus:
Diabetes mellitus induced magnesium deficiency can cause hypocalcemia
and in cases of diabetic nephropathy hypocalcemia can occur due to reduced synthesis
of vitamin D and due to hyperphosphatemia.
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Presence of renal and liver diseases:
Presence of renal disease is known to reduce calcium levels by reducing
vitamin D synthesis, hyperphosphatemia. Liver disease is known to increase alkaline
phosphatase levels and falsely decrease calcium levels due to decrease in serum
albumin levels.
Antitubercular drugs:
Drugs like rifampicin are potent enzyme inducers and can cause similar effects
like antiepileptic drugs.
Duration of treatment and type of therapy :
Increased duration of treatment and consumption of more than one drug type
will increase the severity of hypocalcemia thereby increasing the risk of bone loss and
fractures.
Drug taken:
This helps to decide whether antiepileptic drug taken by the patient is an
enzyme inducer or non enzyme inducer. Only enzyme inducing drugs can cause
abnormalities of bone mineral homeostasis
Drugs causing hypocalcaemia:
1. Heparin
2. Glucagon
3. Protamine sulfate
4. Bisphosphonates
5. Cisplatin
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6. Anticonvulsants
7. Aminoglycosides
8. Proton pump inhibitors
After eliciting the details in the proforma,  patients blood sample are taken for
measuring the levels of calcium, alkaline phosphatase, urea, creatinine, SGOT and
SGPT in the blood.
Hypocalcemia is defined as a decrease in total  serum calcium level less than
8.5 mg/dl with normal serum albumin levels. Alkaline phosphatase levels more than >
140 IU/L are considered high.
The statistical difference between the biochemical parameters was expressed
using p value , F statistic value , odds ratio and ANOVA.
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Method Of Analysis
Patients age ,  sex, type of therapy , duration of therapy, serum calcium and
alkaline phosphatase levels was calculated. The data was compared with the studies
carried out worldwide and in the Indian subcontinent and noted for any differences.
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Ethical Issues
1. The objectives and procedure of the study was explained to all patients.
2. Informed consent was taken from all patients willing to participate in the study.
3. The option to opt out of the study was kept open without any clause.
4. Complete confidentiality regarding patient information was maintained through
all the stages of the study.
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RESULTS
Between 2017 and 2018, 200 cases (patients on antiepileptic therapy)  and 200
controls attending outpatient department in department of neurology in Government
Vellore Medical College Hospital were studied. Among the 230 cases selected, 30
were excluded from the study. The table below shows the baseline characteristics of
the cases and controls included in the study:
TABLE NO – 2 BASELINE CHARACTERISTICS
CHARACTERISTICS CASES CONTROLS
MEAN AGE 31.3 (SD - 9.08) 33.88 (SD - 8.70)
SEX
MALE
96 (48%) 101(50.5%)
FEMALE 104(52%) 99(50.5%)
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TABLE 3 :BIOCHEMICAL PARAMETERS OF CASES AND CONTROLS
PARAMETERS CASES CONTROLS
MEAN ALBUMIN
mg/dl 4.59 (SD- 0.19) 4.53 (SD – 0.23)
MEAN UREA
mg/dl 23.7 (SD-5.1) 20.5(SD-4.5)
MEAN CREATININE
mg/dl 0.75(SD-0.17) 0.73(SD-0.19)
MEAN SGOT
IU/L 20.08(SD-3.7) 20.8(SD-5.2)
MEAN SGPT
IU/L 24.6(SD-4.4) 26.9(SD-5.6)
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FIG NO 7 :FREQUENCY BASED ON TYPE OF THERAPY
Among 200 patients studied, 112 patients were on monotherapy,  60 patients were
on dual therapy and 28 patients were on triple therapy.
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TABLE NO 4: ANTIEPILEPTIC PROFILE OF PATIENTS
TYPE OF
THERAPY NAME OF THE DRUG
NO OF
PATIENTS
MONOTHERAPY
PHENYTOIN 72
CARBAMAZEPINE 24
SODIUM VALPROATE 16
DUAL THERAPY
PHENYTOIN + PHENOBARBITONE 13
PHENYTOIN + CARBAMAZEPINE 21
PHENYTOIN + SODIUM VALPROATE 18
CARBAMAZEPINE + SODIUM
VALPROATE 8
TRIPLE
THERAPY
PHENYTOIN
+PHENOBARBITONE+SODIUM
VALPROATE 3
PHENYTOIN+ PHENOBARBITONE
+CARBAMAZEPINE 25
53
TABLE NO : 5 SEX AND CALCIUM LEVELS
CALCIUM LEVELS
SEX LOW CALCIUM NORMAL CALCIUM
FEMALE 56 48
MALE 48 48
TABLE NO 6 -SEX AND ALKALINE PHOSPHATASE LEVELS
ALKALINE PHOSPHATASE
SEX HIGH NORMAL
FEMALE 60 44
MALE 59 37
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TABLE NO :7 AGE AND CALCIUM LEVELS
CALCIUM LEVELS
AGE LOW NORMAL
16 TO 30 YEARS 37 50
30 TO 55 YEARS 67 46
TABLE NO: 8 AGE AND ALKALINE PHOSPHATASE LEVELS
ALKALINE PHOSPHATASE
AGE HIGH NORMAL
16 TO 30 YEARS 41 46
30 TO 55 YEARS 78 35
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TABLE NO: 9 COMPARISON  OF CALCIUM LEVELS BETWEEN CASES
AND CONTROLS
SERUM  CALCIUM
CASE/CONTROL LOWCALCIUM NORMAL
CASE 97 103
CONTROLS 30 170
The above table compares number of cases and controls with low and normal calcium
levels. The observations  are that, the  patients on antiepileptic therapy are 5.33 times
at higher risk of developing hypocalcaemia than the controls with ODDS RATIO of
5.33 (3.31 TO 8.5).
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TABLE NO: 10 COMPARISON OF HIGH AND NORMAL ALKALINE
PHOSPHATASE LEVELS BETWEEN CASES AND CONTROLS
ALKALINE PHOSPHATASE
CASE/ CONTROL HIGH NORMAL
CASES 119 81
CONTROLS 21 179
Similar to calcium, the above table compares the high and normal  alkaline
phosphatase levels between cases and controls. The observations are that the cases are
12.52 times at greater risk of having high alkaline phosphatase levels than the controls
with a ODDS RATIO of 12.52 (7.34 to 21.33). and P value of 0.00
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TABLE NO: 11 MEAN CALCIUM AND ALKALINE PHOSPHATASE
VALUES OF CASES AND CONTROLS
CHARACTERISTICS CASES CONTROLS
MEAN CALCIUM (mg/dl ) 8.22( SD - 0.94) 9.16(SD - 0.66)
MEAN ALKALINE PHOSPHATASE
(IU/L)
153.98 (SD -
40.07) 93.09 (SD - 34.15)
The table shows the mean calcium and mean alkaline phosphatase levels of
cases and controls. The difference between the two  mean calcium values when
compared using student t test has a T value of -11.5 and P value of 0.00 making it
statistically significant. The mean alkaline phosphatase value is 153.98 with a T value
of 16.35 and P value of 0.00.
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FIG NO: 8 COMPARISON CHART  BETWEEN NO OF CASES AND
CONTROLS WITH LOW AND NORMAL CALCIUM VALUES
The above chart illustrates the number of patients and controls with low and
normal calcium values. Among the patients, based on the type of therapy taken,
patients arecompared, with highest number observed among patients taking triple
therapy.
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TABLE NO: 12 MEAN CALCIUM VALUES OF CASES BASED ON TYPE OF
THERAPY
TYPE OF THERAPY
MEAN
DURATION OF
THERAPY
(in years)
MEAN (and SD)
CALCIUM
VALUES (mg/dl)
MONOTHERAPY 5.18 8.44(0.80)
DUAL THERAPY 5.10 8.27(0.94)
TRIPLE THERAPY 7.87 7.23(0.82)
The above table depicts that the mean calcium values are lowest among
patients taking triple therapy and the difference between the three means is
statistically significant  by ANOVA ( F STATISTIC – 68.7), with a P
VALUE OF 0.002
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FIG NO: 9 COMPARISON CHART  BETWEEN NO OF CASES AND
CONTROLS WITH NORMAL AND HIGH ALKALINE PHOSPHATASE
The above chart depicts the number of patients with normal and high alkaline
phosphatase levels. Patients taking different drug types are compared among
themselves and among the controls. Highest values are observed among patients
taking triple therapy.
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TABLE NO: 13 MEAN ALKALINE PHOSPHATASE OF CASES VALUES
BASED ON TYPE OF THERAPY
TYPE OF THERAPY
MEAN DURATION
OF THERAPY
(in years)
MEAN (SD)ALP
VALUES(IU)
MONOTHERAPY 5.18 142.80 (40.2)
DUAL THERAPY 5.10 159.71(35.5)
TRIPLE THERAPY 7.87 186.39(27.4)
The above table describes that high alkaline phosphatase levels are observed
among patients taking triple therapyand the difference between the three means is
statistically significant  by ANOVA ( F STATISTIC –108.46), with a P VALUE
OF 0.000
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TABLE NO: 14 ANTIEPILEPTIC DRUGS AND MEAN CALCIUM VALUES
TYPE  OF THERAPY Mean Calcium
Values
Std Dev
DUAL THERAPY [PHT+PB] 8.2308 1.1033
DUAL THERAPY[CBZ+SV] 8.5 0.5155
DUAL THERAPY [PHT+CBZ] 7.9952 1.0557
DUAL THERAPY [PHT+SV} 8.5194 0.8148
MONOTHERAPY[CBZ] 8.3167 0.8133
MONOTHERAPY[PHT] 8.4083 0.8297
MONOTHERAPY[SV] 8.8063 0.6148
TRIPLETHERAPY[PHT+PB+CBZ] 7.324 0.8333
TRIPLE THERAPY [PHT+PB+SV] 6.5333 0.3512
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FIGURE NO: 10 FREQUENCY BASED ON DURATION OF THERAPY
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FIGURE NO: 11 COMPARISON CHART BETWEEN NO OF PATIENTS
WITH LOW AND NORMAL CALCIUM LEVELS BASED ON DURATION
The above chart depicts the number of patients with low and normal calcium
values with the duration of therapy.
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FIGURE NO: 12 MEAN CALCIUM VALUES BASED ON DURATION OF
THERAPY
The above chart illustrates that mean calcium value decreases as the duration of
therapy increases.There is significant difference between calcium levels in patients on
antiepileptic therapy for less than 4 years, more than 4 years and more than 9 years by
a ANOVA ( F STATISTIC – 182.81).
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FIGURE NO: 13 COMPARISON CHART BETWEEN NO OF PATIENTS
WITH NORMAL AND HIGH ALKALINE PHOSPHATASE LEVELS BASED
ON DURATION
The chart illustrates that among 45 patients taking drugs for 9 to 16 years, 44 were
found to have high alkaline phosphatase levels. The inference is that as the duration
increases the alkaline phosphatase levels increases among the patients.
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FIGURE NO: 14 MEAN ALKALINE PHOSPHATASE VALUES BASED ON
DURATION OF THERAPY
The above chart illustrates that the mean alkaline phosphatase values increases
as the duration of therapy increases. There is significant difference between calcium
levels in patients on antiepileptic therapy for less than 4 years, more than 4 years and
more than 9 years by a ANOVA ( F STATISTIC –36.922).
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DISCUSSION
Epilepsy is a major public health problem worldwide and in India with a
prevalence of 50 million and 10 million people affected respectively(2). It
predominantly affects people in adolescence and adult age group. Antiepileptics are
the main stay of treatment for this disorder. Taking these drugs for a protracted period
of time and  taking increased number of drugs of different types  affects bone mineral
metabolism and  bone health subclinically , thereby imposing  significant risk of
fractures  which affects the health and quality of life of the patients(8). The minerals
commonly affected are calcium, phosphorus, PTH, vitamin D . The levels of these
minerals are decreased  and hormones like PTH and enzymes like alkaline
phosphatase(7,23,27)are increased due to increased bone turnover.  The metabolic
abnormalities caused by these drugs are less commonly addressed by the treating
physicians.  Also the patients are not monitored regularly for these abnormalities and
are not being supplemented in case of inadequacy. So the  levels bone health markers
like calcium and alkaline phosphatase in patients on chronic antiepileptic therapy and
those  not on antiepileptic therapy and whether they need to be started on
supplementation or not was analysed in detail in this study.
AGE AND EPILEPSY:
In our study 200 consecutive epileptic patients on antiepileptic therapy and 200
age and gender matched controls were taken for the analysis.
In this study, the mean age  of the patients on antiepileptic therapy (cases) and
those not on therapy (controls)  are31.3 ( SD - 9.08) years and 33.8 ( SD - 8.70 )
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years respectively. This closely resembled study done by RICHENS ROWE ET
AL(15)where the mean age was 36 and 34 for cases and controls respectively.
TABLE NO: 15 shows similar studies showing same age group
S.No Studies Mean Age Of Cases And Controls
1. Richens  Rowe et al(15) 34 and 36
2. Ghafghazi et al(18) 23 and 25
3. Shweta Singla et al(52) 37.7 and 35.5
4. Present Study 31.3 and 33.8
The importance of age is that most of the patients in our study, are in adult
group , the period  during which adequate supplementation with minerals will improve
their quality of life and thereby reduces the risk of fracture. The table no.7 and 8
depicts that in our study the number of patients with low calcium and high alkaline
phosphatase levels are more in the age group of 30 to 55 years.
SEX:
In our study, males and females are in the ratio of 1:1 { Cases – 200 ( Males –
96 and Females – 104), Controls- 200 (Males – 101, Females – 99)} . In our study, as
depicted in table 5 and 6, the levels of low calcium and high alkaline phosphatase are
more in female than in males.  A study conducted by Amudhan et al(4) has published
that the prevalence of epilepsy in India is more than in males than in females and in
other study conducted by MARKOULA et al (53)related to gender specific changes in
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BMD in patients on antiepileptic therapy, decrease in BMD is observed more in males
than in females. The variation in our study may be due to existing low calcium levels
in female population due to poor supplementation, low socioeconomic status.
BIOCHEMICAL PARAMETERS:
The measured biochemical parameters like serum albumin, serum urea and
creatinine and serum SGOT and SGPT was not found to have statistically significant
difference between the two groups as shown in table 3.
ANTIEPILEPTICS:
All the cases in our study are on treatment with enzyme inducing antiepileptic
drugs like phenytoin,phenobarbitone, carbamazepine and sodium valproate for a mean
duration of  5.5 years.
Among the 200 cases and 200 controls  analysed, 48% (97 cases) found to
have low calcium values  and 15% ( 30 controls) found to be hypocalcemic. In the
study done by RICHE ROWENS et al(15), it was observed that 22.5% patients
among 160 patients were hypocalcemic.
The mean (+_SD) corrected calcium value of the cases are8.22 +_0.94mg/dl
and that of controls are 9.16 +_0.66 mg/dl. The difference between the mean and
standard error of differences of  corrected calcium  of cases and controls is statistically
significant with a P VALUE of (< 0.05) depicted  in table 11. The mean albumin
concentration of cases and controls is 4.5mg/dl. The mean(SD) calcium of cases and
controls in the study conducted by RICHE ROWENS et al was 9.25(+_ 0.03)mg/dl
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and 9.73 (+_0.05)mg/dl(15). In another study conducted by GHAFGHAZI ET
ALthe mean calcium of cases and controls was 9.2 (+_0.9 )mg/dland 10
(+_0.8)mg/dl(18) respectively. Compared to these studies, the mean calcium of both
cases and controls is low in our study which may be due to low dietary calcium intake,
poor supplementation due to poor socioeconomic status , high phytate content(54,55)
in south Indian diet which inhibits calcium absorption.
Similar to  calcium levels, 59.5% (119 cases) had high alkaline phosphatase
levels and 10.5% ( 21 controls) had high ALP levels. In a study done GHAFGHAZI
ET (18)AL, 41% among 35 patients had increase in alkaline phosphatase levels.
The mean (+_SD) alkaline phosphatase levels of the cases and controls are 153.98
(+_40.07)IU/L and 93.09 ( +_34.15)IU/Lrespectively. The difference between cases
and controls was statistically significant.   The observation is that compared to age and
gender matched controls, patients on antiepileptic therapy are found to have low
calcium and high alkaline phosphatase values which is statistically significant with
a p value of (<0.05)
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The Table No: 16 depicts different studies showing variations in calcium and ALP
levels.
S.NO STUDIES % Of CalciumDecreased
% Of ALP
Increased
1. Richens Rowe et al(15) 22.5 29
2. Shweta Singla et al(52) 8 -
3. Ghafghazi et al(18) - 41
4 Pack et al(17) 3 to 30 -
5 Wright(56) - 20
6. Hunter et al 30 24
7. Present study 48 59.5
The 200 patients on antiepileptic therapy were  subclassified into groups based
on duration and type of therapy and within those groups mean calcium and alkaline
phosphatase levels were analysed.
Based on duration of therapy:
1. MINIMUM - 1 TO 4 YEARS – 84 PATIENTS
2. INTERMEDIATE – 4 TO 9 YEARS – 71 PATIENTS
3. MAXIMUM – 9 TO 16 YEARS – 45 PATIENTS
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The observations are that
1. The mean (+_SD) corrected calcium values are 8.99 (0.51)mg/dl,
8.05(0.68)mg/dl ,7.04 (0.40)mg/dlin the minimum, intermediate and maximum
groups, respectively.
2. The observed alkaline phosphatse levels are 132.4 (37.5)IU/L
,159.1(38.3)IU/L, 186.06(16.8)IU/L respectively.
3. The results are consistent with the study done by RICHENS ROWE(15) et al,
that as the duration of the therapy increases the calcium levels decreases and
alkaline phosphatase increases much beyond normal levels. Also the number of
patients with low calcium levels and high ALP levels increases as duration
increases. This is depicted in the figures 11 to 14.
BASED ON TYPE OF THERAPY:
1. MONOTHERAPY - 112 PATIENTS
2. DUAL THERAPY - 60 PATIENTS
3. TRIPLE THERAPY - 28 PATIENTS
The results are as follows:
1. Mean (+_SD) corrected calcium values are 8.44 (0.80)mg/dl,  8.27 (0.94)mg/dl
,7.23 (0.82mg/dl) in the three groups respectively.
2. Mean (+_SD) alkaline phosphatase levels are 142.80 (40.2)IU/L
,159.71(35.5)IU/L,  186.39 (27.4)IU/L respectively.
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The findings are similar to the studies conducted by RICHEN ROWE(15) et al,
GHAFGHAZI (18)et al and the observations are that compared to monotherapy,
patients on triple therapy are found to have significantly lower calcium and higher
alkaline phosphatase levels. In a study conducted by RICHENS ROWE et al, the
mean calcium of monotherapy, dual therapy and triple therapy was 9.48 (SD+_
0.12)mg/dl, 9.29 (SD+_0.04)mg/dl and 9.02 (SD+_0.07)mg/dl respectively. This
finding is also low in our study as depicted in figures 8 and 9 and tables 12 and 13.
It is inferred that as the duration of therapy and number of drugs increases the
mean calcium  and alkaline phosphatase levels decreases and increases respectively.
Among the patients taking different types of therapy,
• In monotherapy group, the mean calcium levels are lowest in
carbamazepine group - 8.31 (SD0.8 )mg/dl ,
• In dual therapy it is lowest inphenytoin and carbamazepine group – 7.99
(SD-1.05)mg/dl
• In triple therapy it is lowest in phenytoin, phenobarbitone and sodium
valproate group.
The findings are showed in table 14.
In a study conducted by GHAFGHAZI (18)et al, among dual therapy lower
calcium levels were found in  patients on phenytoin and phenobarbitone and in triple
therapy for patients on PHT, PB and CBZ because sodium valproate was not included
in their study.
75
History of neck surgery, radiation, jaundice and alcohol was found  to have no
confounding effect on the results obtained.
LIMITATIONS:
• Serum levels of vitamin D, phosphorus and parathyroid hormone and the bone
mineral density using DEXA could not be measured due to nonavailability of
resources.
• The nutritional status and BMI of the patients was not assessed.
• History of smoking and any thyroid disorders known to have confounding risk
was not elicited.
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CONCLUSIONS AND RECOMMENDATIONS
Between October 2017 and August 2018, 200 patients on antiepileptic therapy
and 200 controls were studied in the outpatient department, in the Department Of
Neurology In Government Vellore Medical College Hospital.
• The calcium and alkaline phosphatase levels were analysed in both the groups.
• Compared to controls, patients on antiepileptic therapy found to have low
serum calcium and high alkaline phosphatase levels.
• Prevalence of hypocalcemia was found to be 48% among patients on
antiepileptic patients.
• Among cases, patients in the age group of 30 to 55 years, found to have lower
calcium and high alkaline phosphatase levels compared to  that in18 to 30
years.
• Also Females had lower calcium levels compared to males.
• It was also inferred that as the duration of therapy and number of drugs
increased, mean calcium and alkaline phosphatase levels is decreased and
increased respectively.
• So the physicians treating  the patients who are on antiepileptic therapy for
chronic duration should give awareness to their patients regarding the possible
effects of these drugs on bone mineral metabolism , increased fracture risk and
counsel them to avoid intake of factors like alcohol, smoking, steroids and
other drugs which can increase the bone loss.
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• They should also be counselled to periodically monitor the levels of bone
health markers like calcium, phosphorus,vitamin D and alkaline phosphatase in
a interval of at least6 months and to be started on adequate supplementation
with calcium and vitamin D3 if low levels are detected or if they have multiple
risk factors.
They should be advised to have adequate sunlight exposure, to consume diet rich
in calcium, vitamin D like diary products, fortified cereals and be started on calcium
supplementation around 1000 to 1500 mg/d.
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PROFORMA
NAME                       :
AGE/SEX                  :
OP NO                        :
OCCUPATION          :
ADDRESS                :
H/O ANY SURGERY IN THE NECK:
H/O ANY ACUTE ABDOMEN IN THE PAST:
H/O ANY RADIATION TO THE NECK IN THE PAST:
PAST H/O JAUNDICE:
COMORBITIES:
SYSTEMIC HYPERTENSION – YES/NO
DIABETES MELLITUS – YES/NO
SEIZURE DISORDER – YES/NO { IF YES – DURATION -
TUBERCULOSIS – YES/NO
KIDNEY DISEASE – YES/ NO
ALCOHOLISM:
DURATION :
AMOUNT CONSUMED PER DAY:
DRUG HISTORY:
ANTIEPILEPTICS-
Phenytoin/Carbmazepine/Phenobarbitone/others
Duration –
MONOTHERAPY / POLYTHERAPY
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IF POLYTHERAPY -
• DRUGS FOR OTHER COMORBITIES :
DURATION -
LABORATORY INVESTIGATIONS:
SERUM CALCIUM                            :
LIVER FUNCTION TEST : ALP –
SGOT-
SGPT-
RENAL FUNCTION TEST                 :
SERUM ALBUMIN                             :
CORRECTED CALCIUM VALUE :
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C Sathish kumar 36 M 794836 N N N N N N Y N 2 M[P] 7.9 160 4.3 7.9 36 0.9 26 20
C Sultan 34 M 867543 N N N N N N Y N 5 M[P] 7.8 175 4.8 7.8 30 0.7 25 18
C Dinakaran 32 M 679482 N N N N N N Y N 1.5 M[P] 8 166 4.7 8 26 0.4 20 18
C Nagarajan 39 M 828053 N N N N N N Y N 8 M[P] 7.6 176 4.3 7.6 32 0.6 18 26
C Vignesh 29 M 816040 N N N N N N Y N 10 M[P] 7.3 176 4.5 7.3 24 0.8 16 22
C Kamala 32 F 54028 N N N N N N Y N 7 M[P] 7.7 196 4.7 7.7 22 0.9 22 18
C Jayalakshmi 44 F 828209 N N N N N N Y N 9 M[P] 7.4 172 4.4 7.4 28 0.8 19 22
C Ellammal 49 F 826450 N N N N N N Y N 11 M[P] 7.3 194 4.9 7.3 38 0.8 22 26
C Swetha 10 F 53803 N N N N N N Y N 10 M[P] 7.4 176 4.3 7.4 22 .0.8 20 24
C Gopalakrishnan 27 M 827982 N N N N N N Y N 12 M[P] 7.1 182 4.4 7.1 32 0.8 16 22
C Pandu rangan 44 M 170160 N N N N N N Y N 16 M[P] 6.9 184 4.6 6.9 26 0.8 22 26
C Menaka 30 F 55364 N N N N N N Y N 10 M[P] 7.3 176 4.4 7.3 22 0.9 22 26
C Samuel 29 M 825302 N N N N N N Y N 12 M[P] 7 200 4.9 7 28 0.9 22 26
C Perumal 18 M 54847 N N N N N N Y N 8 M[P] 7.5 196 4.3 7.5 22 0.9 22 24
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C Perumal 30 M 54328 N N N N N N Y N 11 M[P] 7 212 4.6 7 20 0.7 28 13
C Hemavathy 22 F 82523 N N N N N N Y N 7 M[P] 7.4 182 4.7 7.4 34 0.8 22 26
C Bulush 22 F 825435 N N N N N N Y N 14 M[P] 7.2 188 4.8 7.2 22 0.8 22 24
C Manjula 27 F 821573 N N N N N N Y N 9 M[P] 7.7 194 4.9 7.7 22 0.8 18 24
C Selvaraj 47 M 50178 N N N N N N Y N 2 M[P] 8.8 56 4.4 8.8 25 1 42 24
C Samathar 44 F 90954 N N N N N N Y N 4 M[P] 9.2 100 4.4 9.2 14 1 19 17
C Devanayagi 40 F 122303 N N N N N N Y N 6 M[P] 9 102 4.6 9 25 1 16 22
C Vignesh 18 M 506485 N N N N N N Y N 2 M[P] 9 114 4.9 9 25 0.9 22 26
C Vengadabthi 44 M 347013 N N N N N N Y N 4 M[P] 8.5 122 4.9 8.5 25 0.8 18 22
C Sasikala 27 F 126782 N N N N N N Y N 5 M[P] 8.4 136 4.7 8.4 28 0.9 18 24
C Sekar 46 M 104716 N N N N N N Y N 3 M[P] 8.8 135 4.6 8.8 26 0.9 18 24
C Amutha 37 F 435157 N N N N N N Y N 2 M[P] 10.2 162 4.4 10.2 26 0.7 18 25
C Perumal 19 M 590069 N N N N N N Y N 4 M[P] 9.2 142 4.5 9.2 22 0.6 16 22
C Latha 38 F 182461 N N N N N N Y N 3 M[P] 9.4 132 4.6 9.4 22 0.7 22 26
C Kamachi 34 F 441329 N N N N N N Y N 5 M[P] 9.4 135 4.6 9.4 21 0.9 18 20
C Ramalingam 39 M 131338 N N N N N N Y N 3 M[P] 8.7 122 4.6 8.7 18 0.4 18 24
C Ravi 40 M 585763 N N N N N N Y N 2.5 M[P] 8.7 110 4.6 8.7 21 0.9 16 22
C Pooja 20 F 119339 N N N N N N Y N 4 M[P] 8.6 135 4.7 8.6 18 0.5 18 16
C Mahesh 20 M 121612 N N N N N N Y N 2 M[P] 8.7 121 4.7 8.7 22 0.8 12 18
C Kantha 22 F 594877 N N N N N N Y N 3 M[P] 8.8 142 4.6 8.8 22 0.9 16 19
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C Kumaresan 24 M 97933 N N N N N N Y N 2.5 M[P] 9.2 136 4.6 9.2 22 0.7 18 16
C Chandra 35 F 351413 N N N N N N Y N 5 M[P] 8.4 150 4.6 8.4 20 0.7 18 22
C Chandrika 18 F 297267 N N N N N N Y N 3 M[P] 9 110 4.7 9 19 0.8 16 20
C Chniraj 46 M 84991 N N N N N N Y N 3 M[P] 9.2 98 4.8 9.2 20 0.7 16 20
C Rajeswari 36 F 180611 N N N N N N Y N 5 M[P] 8.6 112 4.6 8.6 18 0.9 14 18
C Manjula 40 F 546191 N N N N N N Y N 2 M[P] 9.6 80 4.6 9.6 18 0.9 14 20
C Selvarasu 29 M 516328 N N N N N N Y N 3 M[P] 8.8 110 4.7 8.8 19 0.8 16 20
C Selvaraj 44 M 810811 N N N N N N Y N 2 M[P] 9.2 110 4.7 9.2 16 0.9 18 20
C Dharshini 18 F 151642 N N N N N N Y N 3 M[P] 9.2 114 4.6 9.2 18 0.9 16 24
C Vignesh 20 M 51393 N N N N N N Y N 4 M[P] 8.5 132 4.6 8.5 18 1 16 22
C Rajendiran 40 M 51478 N N N N N N Y N 6 M[P] 8.3 130 4.7 8.3 26 0.7 17 14
C Thamina 20 F 747944 N N N N N N Y N 3 M[P] 8.6 96 4.8 8.6 22 0.9 14 20
C Rubini 22 F 815391 N N N N N N Y N 2 M[P] 8.9 80 4.8 8.9 26 0.8 14 22
C Subash 20 M 402029 N N N N N N Y N 5 M[P] 8.4 122 4.6 8.4 22 0.7 18 14
C Ramakrishnan 45 M 55499 N N N N N N Y N 3 M[P] 9.4 124 4.7 9.4 20 0.4 16 20
C Pavithra 18 F 88658 N N N N N N Y N 4 M[P] 8.8 86 4.7 8.8 28 0.9 20 22
C Praveen kumar 19 M 808013 N N N N N N Y N 2 M[P] 9.2 92 4.6 9.2 26 0.5 22 26
C Venda 28 F 88698 N N N N N N Y N 5 M[P] 8.3 86 4.4 8.3 18 0.3 20 24
C Rajalakshmi 19 F 804089 N N N N N N Y N 2.5 M[P] 9.6 84 4.8 9.6 20 1 21 22
C Lakshmi 40 F 818702 N N N N N N Y N 3.5 M[P] 9.1 100 4.2 9.1 18 0.1 26 22
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C Fathima 30 F 173768 N N N N N N Y N 4.5 M[P] 8.5 92 4.3 8.5 19 0.4 22 24
C Balaji 44 M 173822 N N N N N N Y N 2 M[P] 9.8 96 4.4 9.8 26 0.8 16 20
C Sankar 30 M 173218 N N N N N N Y N 3.5 M[P] 8.9 104 4.4 8.9 16 0.8 22 26
C Deepak kumar 19 M 810089 N N N N N N Y N 5 M[P] 8.6 112 4.6 8.6 34 0.8 23 26
C Deepan sakra 27 M 438801 N N N N N N Y N 2.5 M[P] 9.3 95 4.6 9.3 28 0.8 20 24
C Janani 28 F 812859 N N N N N N Y N 3.5 M[P] 8.9 98 4.5 8.9 18 0.8 22 26
C Yukesh 20 M 799367 N N N N N N Y N 2 M[P] 9.8 96 4.6 9.8 18 0.4 20 24
C Ganesan 41 M 815596 N N N N N N Y N 3 M[P] 9.2 100 4.3 9.2 32 0.8 20 26
C Yasmin 23 F 699734 N N N N N N Y N 3 M[P] 7.9 180 4.8 7.9 22 0.7 19 22
C Usha 30 F 407527 N N N N N N Y N 3 M[P] 7.8 162 4.6 7.8 23 0.9 18 24
C Anitha 18 F 746767 N N N N N N Y N 2 M[P] 8.2 130 4.7 8.2 22 0.7 18 25
C Shakir 18 M 354980 N N N N N N Y N 2 M[P] 8.1 120 4.6 8.1 28 0.5 22 18
C Revathy 29 F 654473 N N N N N N Y N 3 M[P] 7.9 168 4.9 7.9 17 0.4 16 24
C Ponnarasu 23 M 649425 N N N N N N Y N 12 M[P] 6.9 176 4.9 6.9 32 0.8 12 24
C Amutha 37 F 435157 N N N N N N Y N 10 M[P] 7.3 172 4.7 7.3 28 0.9 18 32
C Amsa 35 F 342235 N N N N N N Y N 12 M[P] 6.8 176 4.7 6.8 28 0.4 18 26
C Perumal 20 M 590069 N N N N N N Y N 5 M[P] 8 176 4.8 8 26 0.9 25 22
C Varadhan 55 M 803022 N N N N N N Y N 2 M[CB] 8 160 4.7 8 34 0.8 20 22
C Selvi 40 F 376319 N N N N N N Y N 2 M[CB] 8.1 175 4.8 8.1 22 0.7 22 18
C Selvam 44 M 139238 N N N N N N Y N 10 M[CB] 7.8 178 4.7 7.8 22 0.8 19 25
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C Varadhan 25 M 805134 N N N N N N Y N 8 M[CB] 7.9 186 4.7 7.9 28 0.9 22 25
C Selvanayagi 23 F 385427 N N N N N N Y N 9 M[CB] 7.6 192 4.4 7.6 29 0.5 22 24
C Ranjitha 25 F 129754 N N N N N N Y N 12 M[CB] 7.2 120 4.5 7.2 28 0.5 21 26
C Munisami 36 M 129639 N N N N N N Y N 7 M[CB] 8 156 4.7 8 18 0.4 22 26
C Ammu 31 F 354836 N N N N N N Y N 10 M[CB] 7.4 162 4.7 7.4 20 0.8 22 24
C Selvarani 34 F 218127 N N N N N N Y N 13 M[CB] 7.3 210 4.8 7.3 19 0.8 18 22
C Chinnaponnu 36 F 75882 N N N N N N Y N 11 M[CB] 7.5 177 4.6 7.5 28 0.5 21 25
C Shankari 34 F 81723 N N N N N N Y N 9 M[CB] 7.6 196 4.9 7.6 28 0.8 22 26
C Deivanai 30 F 176201 N N N N N N Y N 13 M[CB] 7.2 211 4.7 7.2 18 0.3 22 26
C Karthika 22 F 33609 N N N N N N Y N 5 M[CB] 8.2 126 4.6 8.2 32 0.9 19 22
C Priya 19 F 812106 N N N N N N Y N 2 M[CB] 9.6 98 4.9 9.6 22 0.8 12 16
C Naveen 22 M 813036 N N N N N N Y N 3 M[CB] 9.3 112 4.9 9.3 18 0.8 18 24
C Vasantha 45 F 811134 N N N N N N Y N 3 M[CB] 9.3 122 4.3 9.3 28 0.6 19 22
C Ramamoorthy 40 M 810514 N N N N N N Y N 5 M[CB] 8.4 165 4.6 8.4 18 1 22 28
C Ezhilarasi 24 F 811135 N N N N N N Y N 2 M[CB] 9.4 120 4.7 9.4 13 0.5 18 26
C Jothi 40 F 810842 N N N N N N Y N 4 M[CB] 8.7 132 4.6 8.7 19 0.8 17 26
C Janani 20 F 46179 N N N N N N Y N 2 M[CB] 9.7 118 4.6 9.7 19 0.8 21 26
C Gowtham raj 21 M 163360 N N N N N N Y N 4 M[CB] 8.6 98 4.7 8.6 18 0.4 26 21
C Soundari 28 F 448963 N N N N N N Y N 3 M[CB] 8.9 102 4.6 8.9 18 0.5 19 24
C Kalaivani 24 F 50422 N N N N N N Y N 3 M[CB] 8.5 124 4.7 8.5 20 0.9 18 26
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C Devi 27 F 51833 N N N N N N Y N 2 M[CB] 9.4 100 4.8 9.4 20 0.9 19 25
C Kishore 24 M 800821 N N N N N N Y N 8 M[SV] 7.9 186 4.6 7.9 28 0.9 22 29
C Kandasamy 45 M 804899 N N N N N N Y N 10 M[SV] 7.7 186 4.9 7.7 28 0.8 21 26
C Jayakarthikey 24 M 799781 N N N N N N Y N 7 M[SV] 8.2 196 4.7 8.2 26 0.9 22 29
C Gopal 47 M 808185 N N N N N N Y N 6 M[SV] 8 210 4.5 8 24 0.9 21 26
C Kamachi 39 F 563298 N N N N N N Y N 3 M[SV] 8.9 196 4.7 8.9 32 0.8 22 29
C Gowtham 18 M 808924 N N N N N N Y N 2 M[SV] 8.9 192 4.6 8.9 22 0.9 16 22
C Krishnamoorthi 20 M 808930 N N N N N N Y N 4 M[SV] 8.7 213 4.6 8.7 28 0.7 22 32
C Selvi 40 F 807998 N N N N N N Y N 5 M[SV] 8.6 152 4.7 8.6 28 0.5 22 29
C Saranya 23 F 808484 N N N N N N Y N 2 M[SV] 9.6 96 4.2 9.6 28 1 22 34
C Thilagam 42 F 54470 N N N N N N Y N 2.5 M[SV] 9.6 90 4.3 9.6 28 1 22 26
C Gomathi 25 F 764243 N N N N N N Y N 4 M[SV] 9.2 120 4.6 9.2 18 0.8 16 20
C Selvi 38 M 807991 N N N N N N Y N 3 M[SV] 9.8 102 4.2 9.8 18 0.5 12 28
C Murugan 37 M 809163 N N N N N N Y N 3 M[SV] 9.1 159 4.4 9.1 32 0.6 22 28
C Darshan 19 M 47193 N N N N N N Y N 3.5 M[SV] 9 203 4.5 9 22 0.8 21 25
C Revathi 25 F 306925 N N N N N N Y N 4 M[SV] 8.8 179 4.9 8.8 22 0.5 22 28
C Kalpana 26 F 806987 N N N N N N Y N 2.5 M[SV] 8.9 220 4.7 8.9 22 0.9 22 30
C Venkatesan 45 M 43670 N N N N N N Y N 8 D[CB+SV] 7.6 204 4.6 7.6 22 0.7 22 26
C Priya 18 F 791397 N N N N N N Y N 4 D[CB+SV] 8.3 132 4.7 8.3 28 0.8 26 39
C Jayamary 47 F 795300 N N N N N N Y N 3 D[CB+SV] 8.6 196 4.7 8.6 28 0.9 18 26
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C Venkatesan 40 M 795102 N N N N N N Y N 3 D[CB+SV] 8.8 182 4.7 8.8 32 0.7 22 28
C Pooja 19 F 796123 N N N N N N Y N 2.5 D[CB+SV] 9 179 4.6 9 28 0.5 21 25
C Padma 40 F 797244 N N N N N N Y N 3.5 D[CB+SV] 8.4 169 4.9 8.4 18 0.7 22 29
C Santhosh 21 M 797257 N N N N N N Y N 5 D[CB+SV] 8.1 136 4.7 8.1 17 0.8 22 29
C Ramakrishnan 25 M 79748 N N N N N N Y N 2 D[CB+SV] 9.2 126 4.6 9.2 18 0.5 18 20
C Mohankumar 35 M 78941 N N N N N N Y N 3 D [P+SV} 7.9 166 3.8 7.95 28 0.4 22 18
C Lakshmi 40 F 742009 N N N N N N Y N 9 D [P+SV} 7.6 180 4.6 7.6 28 0.6 22 32
C Vijayalakshmi 29 F 47890 N N N N N N Y N 6 D [P+SV} 7.9 162 4.6 7.9 28 0.9 18 24
C Sudha 25 F 46000 N N N N N N Y N 8 D [P+SV} 7.5 195 4.6 7.5 22 0.8 22 32
C Kamal basha 45 M 794935 N N N N N N Y N 12 D [P+SV} 6.8 200 4.6 6.8 28 0.9 22 26
C Damotharan 34 M 794701 N N N N N N Y N 10 D [P+SV} 7.3 159 4.3 7.3 28 0.9 22 30
C Sandhiya 17 F 672932 N N N N N N Y N 2 D [P+SV} 9.2 120 4.2 9.2 22 0.9 20 26
C Lathamaheshwari 30 F 291372 N N N N N N Y N 4 D [P+SV} 8.7 110 4.3 8.7 18 0.6 20 24
C Sekar raj 40 M 233625 N N N N N N Y N 3.5 D [P+SV} 8.9 86 4.6 8.9 22 0.9 18 20
C Sandhiya 20 F 672932 N N N N N N Y N 4 D [P+SV} 8.5 136 4.3 8.5 22 0.9 22 28
C Deepa 24 F 41983 N N N N N N Y N 2 D [P+SV} 9.3 186 4.3 9.3 28 0.4 20 24
C Thirupathy 23 M 44063 N N N N N N Y N 3 D [P+SV} 9.3 178 4.4 9.3 22 0.7 22 26
C Velu 40 M 384381 N N N N N N Y N 3.5 D [P+SV} 9 164 4.5 9 28 0.6 22 29
C Nazema 30 F 490096 N N N N N N Y N 2 D [P+SV} 9.6 172 4.5 9.6 19 0.8 22 36
C Murali 35 M 792725 N N N N N N Y N 2.5 D [P+SV} 9.3 132 4.5 9.3 20 0.9 22 28
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C Saravanan 39 M 43600 N N N N N N Y N 3 D [P+SV} 8.9 128 4.3 8.9 32 0.9 22 29
C Vinoth 28 M 798893 N N N N N N Y N 4 D [P+SV} 8.6 104 4.2 8.6 18 0.8 22 29
C Siva 22 M 825682 N N N N N N Y N 3 D [P+SV} 9 98 4.3 9 28 0.9 21 19
C Nadhiya 31 F 346050 N N N N N N Y N 10 D [P+C] 6.6 190 3.9 6.7 24 0.4 21 25
C Megala 32 F 645234 N N N N N N Y N 5 D [P+C] 7.6 182 4.8 7.6 22 0.9 19 25
C Mohankumar 33 M 217894 N N N N N N Y N 4 D [P+C] 7.8 185 4.7 7.8 22 0.4 22 24
C Kamachi 34 F 441329 N N N N N N Y N 6 D [P+C] 6.9 220 4.7 6.9 28 0.9 19 26
C Megaladevi 35 F 734123 N N N N N N Y N 6 D [P+C] 7.5 166 4.6 7.5 22 0.8 22 30
C Monikaselvi 32 M 336563 N N N N N N Y N 9 D [P+C] 6.8 198 4.6 6.8 18 0.6 20 26
C Sultana 36 M 635732 N N N N N N Y N 12 D [P+C] 6.4 192 4.6 6.4 19 0.8 18 20
C Murugan 45 M 768420 N N N N N N Y N 8 D [P+C] 7.5 206 4.6 7.5 18 0.8 18 24
C Umapathi 40 M 797330 N N N N N N Y N 11 D [P+C] 6.6 183 4.8 6.6 19 0.8 22 26
C Meenakshi 31 F 785583 N N N N N N Y N 7 D [P+C] 7.6 186 4.6 7.6 19 0.8 20 25
C Sathish 19 M 799670 N N N N N N Y N 3 D [P+C] 9.2 176 4.6 9.2 17 0.7 20 25
C Nirmal kumar 24 M 772018 N N N N N N Y N 4 D [P+C] 8.8 198 4.4 8.8 18 0.8 18 24
C Subramani 38 M 797898 N N N N N N Y N 3.5 D [P+C] 8.9 204 4.2 8.9 18 0.8 19 25
C Rani 30 F 797828 N N N N N N Y N 7 D [P+C] 7.5 132 4.7 7.5 22 0.8 22 36
C Kanishka 18 F 997783 N N N N N N Y N 2 D [P+C] 9.3 112 4.6 9.3 20 0.7 22 26
C Meena 30 F 798156 N N N N N N Y N 8.5 D [P+C] 7.2 193 4.8 7.2 20 0.7 21 28
C Murugendiran 36 M 797631 N N N N N N Y N 3.5 D [P+C] 9 152 4.7 9 20 0.6 28 19
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C Vikram 18 M 797959 N N N N N N Y N 1.5 D [P+C] 9.8 110 4.6 9.8 18 0.9 28 33
C Saravanan 33 M 796021 N N N N N N Y N 4.5 D [P+C] 8.6 118 4.3 8.6 19 0.5 22 30
C Poongodhai 39 F 150289 N N N N N N Y N 3 D [P+C] 9.3 98 4.7 9.3 20 0.8 12 22
C Devagi 36 F 800855 N N N N N N Y N 3.5 D [P+C] 8.9 126 4.8 8.9 20 0.9 18 24
C Lalitha 35 F 62471 N N N N N N Y N 8 D  [P+PB] 8 166 4.6 8 22 0.8 20 18
C Raja 25 M 128292 N N N N N N Y N 6 D  [P+PB] 7.4 180 4.8 7.4 21 0.9 21 25
C Rukmani 43 F 791799 N N N N N N Y N 7 D  [P+PB] 6.9 178 4.6 6.9 18 0.9 21 32
C Murali 32 M 791601 N N N N N N Y N 10 D  [P+PB] 6.5 195 4.6 6.5 20 0.7 18 22
C Yuvaraj 25 M 790276 N N N N N N Y N 3 D  [P+PB] 8.9 163 4.6 8.9 28 0.9 21 32
C Shilpa 23 F 54689 N N N N N N Y N 7 D  [P+PB] 7.2 169 4.5 7.2 22 0.7 22 38
C Velan 40 M 803012 N N N N N N Y N 9 D  [P+PB] 7.1 159 4.6 7.1 20 0.8 21 26
C Nandhini 19 F 802559 N N N N N N Y N 4 D [P+PB] 8.9 162 4.9 8.9 28 0.8 22 38
C Monika 21 F 796089 N N N N N N Y N 2 D  [P+PB] 9.6 82 4.7 9.6 20 0.8 21 29
C Abdul 36 M 803469 N N N N N N Y N 3.5 D  [P+PB] 8.9 172 4.3 8.9 20 0.5 18 20
C Chithra 39 F 55826 N N N N N N Y N 1.5 D  [P+PB] 9.8 82 4.6 9.8 22 0.9 16 20
C
Lakshmi
narasimhan
43 M 46409 N N N N N N Y N 2.5 D  [P+PB] 9.2 152 4.7 9.2 20 0.8 21 16
C Sekar 36 M 807023 N N N N N N Y N 5 D  [P+PB] 8.6 196 4.3 8.6 18 0.5 20 16
C Anandhi 34 F 116840 N N N N N N Y N 12
TRI
[P+PB+CB
6.9 175 4.6 6.9 32 0.8 19 22
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C Thayar 26 F 353374 N N N N N N Y N 8
TRI
[P+PB+CB
6.3 196 4.8 6.3 32 0.5 18 25
C Sekar 43 M 104716 N N N N N N Y N 6
TRI
[P+PB+CB
6.3 184 4.7 6.3 32 0.9 24 28
C Latha 34 F 182461 N N N N N N Y N 6
TRI
[P+PB+CB
6.6 200 4.4 6.6 32 0.9 16 22
C Kalaivani 24 F 50422 N N N N N N Y N 8
TRI
[P+PB+CB
7.2 215 4.6 7.2 32 0.8 12 24
C Devi 32 F 51823 N N N N N N Y N 11
TRI
[P+PB+CB
7 196 4.9 7 28 0.2 18 26
C Jayasri 28 F 50736 N N N N N N Y N 6
TRI
[P+PB+CB
7.6 192 4.6 7.6 26 0.9 18 26
C Rajasekar 40 M 50831 N N N N N N Y N 10
TRI
[P+PB+CB
7 186 4.5 7 32 0.8 22 28
C Yasodha 37 F 52033 N N N N N N Y N 9
TRI
[P+PB+CB
7.2 192 4.4 7.2 32 0.8 18 26
C Raziya 39 F 815091 N N N N N N Y N 12
TRI
[P+PB+CB
6.5 200 4.2 6.5 32 0.7 22 26
C Suresh 28 M 44958 N N N N N N Y N 7
TRI
[P+PB+CB
7.3 210 4.6 7.3 32 0.7 22 28
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C Ramesh 32 M 63080 N N N N N N Y N 8
TRI
[P+PB+CB
7.2 198 4.8 7.2 28 0.7 16 20
C Monika 19 F 804019 N N N N N N Y N 5
TRI
[P+PB+CB
7.6 210 4.5 7.6 28 0.7 18 25
C Kandasamy 45 M 80499 N N N N N N Y N 13
TRI
[P+PB+CB
6.8 182 4.7 6.8 28 0.5 41 29
C Ramu 49 M 132768 N N N N N N Y N 9
TRI
[P+PB+CB
6.7 210 4.6 6.7 25 0.9 23 32
C Lalitha 37 F 184173 N N N N N N Y N 11
TRI
[P+PB+CB
6.3 198 4.8 6.3 32 0.9 22 29
C Thilaga 36 F 464282 N N N N N N Y N 10
TRI
[P+PB+CB
6.8 212 4.8 6.8 32 0.9 22 26
C Sasi 32 M 217893 N N N N N N Y N 11
TRI
[P+PB+CB
6.5 199 4.6 6.5 20 1 22 32
C Revathi 29 F 803956 N N N N N N Y N 5
TRI
[P+PB+CB
7.8 198 4.7 7.8 19 0.9 22 30
C Kalpana 28 F 806987 N N N N N N Y N 3
TRI
[P+PB+CB
8.4 189 4.7 8.4 28 0.9 22 26
C Pongodi 32 F 790924 N N N N N N Y N 4
TRI
[P+PB+CB
8.3 166 4.9 8.3 32 0.9 19 28
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C Ramar 45 M 32149 N N N N N N Y N 2
TRI
[P+PB+CB
9 206 4.3 9 22 0.9 22 29
C Sumathi 43 F 393825 N N N N N N Y N 3
TRI
[P+PB+CB
8.8 110 4.3 8.8 28 0.8 22 26
C Mubarak 22 F 52434 N N N N N N Y N 3
TRI
[P+PB+CB
8.6 118 4.8 8.6 20 0.5 20 26
C Pandiyan 46 M 671289 N N N N N N Y N 4.5
TRI
[P+PB+CB
8.4 120 4.6 8.4 22 0.9 21 26
C Anandh 34 M 225739 N N N N N N Y N 12
TRI[P+PB
+SV]
6.5 189 4.8 6.5 22 0.9 22 16
C Rajesh 37 M 252869 N N N N N N Y N 9
TRI[P+PB
+SV]
6.9 176 4.7 6.9 18 1 22 32
C Latha selvi 42 F 204629 N N N N N N Y N 13
TRI[P+PB
+SV]
6.2 192 4.9 6.2 32 0.9 11 25
C Santhoshwaran 22 M 615428 N N N N N N N N 4 M[P] 8.3 78 4.5 8.3 20 0.5 18 23
CO Jayasri 24 F 50724 N N N N N N N N - - 9.9 46 4.3 9.9 24 0.5 22 43
CO Loganathan 19 M 817211 N N N N N N N N - - 9.8 88 4.3 9.8 18 0.5 17 28
CO Kalaiarasi 40 F 817170 N N N N N N N N - - 10.2 96 4.5 10.2 22 0.9 22 42
CO Boopalan 36 M 31691 N N N N N N N N - - 8.9 48 4.1 8.9 17 0.4 17 21
CO Mahalakshmi 20 F 165315 N N N N N N N N - - 8.7 107 4.6 8.7 28 1 26 30
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CO Vasantha 40 F 163652 N N N N N N N N - - 9.9 71 4.3 9.9 20 0.9 22 30
CO Mohan 36 M 632723 N N N N N N N N - - 9.6 68 4.1 9.6 18 0.7 19 26
CO Sajithabegam 23 F 191236 N N N N N N N N - - 9.3 55 4 9.3 16 0.5 16 22
CO Prasanth 29 M 51629 N N N N N N N N - - 9.8 112 4.5 9.8 16 0.8 18 36
CO Malar 40 F 818692 N N N N N N N N - - 9.1 78 4.8 9.1 19 0.4 18 32
CO Prabakaran 42 M 923661 N N N N N N N N - - 9.1 38 4.4 9.1 20 0.4 18 23
CO Chakkaravarthi 40 M 747621 N N N N N N N N - - 10.3 105 4.9 10.3 24 0.6 32 36
CO Kuppusamy 45 M 645671 N N N N N N N N - - 8.6 63 4.2 8.6 17 0.8 20 28
CO Priyalakshmi 21 F 931645 N N N N N N N N - - 8.9 76 4.4 8.9 21 0.5 23 34
CO Lokesh 18 M 456210 N N N N N N N N - - 9.4 89 4.8 9.4 24 1.1 26 32
CO Gopi 25 M 931647 N N N N N N N N - - 9.7 92 4.6 9.7 20 1 29 31
CO Kanaka 48 F 52526 N N N N N N N N - - 8.7 52 4.3 8.7 18 0.5 18 29
CO Venda 27 F 51484 N N N N N N N N - - 9.6 82 4.3 9.6 18 0.6 16 28
CO Yasotha 36 F 801179 N N N N N N N N - - 9.8 112 4.7 9.8 18 0.8 22 29
CO Elango 43 M 78372 N N N N N N N N - - 9.3 92 4.9 9.3 22 0.5 18 32
CO Renuka 39 F 788716 N N N N N N N N - - 8.9 76 4.2 8.9 17 0.8 18 32
CO Balaji 22 M 821438 N N N N N N N N - - 9.6 92 4.9 9.6 28 0.8 22 28
CO Ramakrishnan 42 M 81775 N N N N N N N N - - 9.8 86 4.8 9.8 18 0.9 18 20
CO Abdulla 45 M 51751 N N N N N N N N - - 8.8 99 4.9 8.8 19 0.6 20 32
CO Parithra 20 F 822393 N N N N N N N N - - 9.8 102 4.3 9.8 17 0.4 18 26
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CO Mohan 18 M 817595 N N N N N N N N - - 9.3 82 4.5 9.3 19 0.8 16 26
CO Lakshmi 43 F 826204 N N N N N N N N - - 9.3 132 4.4 9.3 18 0.8 16 20
CO Dhanam 36 F 55423 N N N N N N N N - - 8.8 112 4.4 8.8 18 0.9 18 25
CO Tamilselvi 25 F 54845 N N N N N N N N - - 8.7 122 4.3 8.7 18 0.8 18 26
CO Babu 25 M 824859 N N N N N N N N - - 9.1 104 4.3 9.1 19 0.5 22 28
CO Bajo 48 M 826198 N N N N N N N N - - 9.7 112 4.6 9.7 18 0.4 17 22
CO Shanmugam 32 M 55525 N N N N N N N N - - 9.3 98 4.2 9.3 18 0.7 46 14
CO Marsaiyyam 46 M 55096 N N N N N N N N - - 8.8 112 4.2 8.8 28 1 38 24
CO Pandu rayan 45 M 82982 N N N N N N N N - - 9.7 49 4.2 9.7 35 1.2 24 20
CO Sethu 42 M 82963 N N N N N N N N - - 8.9 72 4.3 8.9 18 0.8 14 23
CO Kamala 38 F 131647 N N N N N N N N - - 9.7 97 4.7 9.7 24 1.2 28 18
CO Subba 32 M 133762 N N N N N N N N - - 9.4 84 4.5 9.4 22 1 25 32
CO Bhuranesh 22 M 50590 N N N N N N N N - - 10.8 27 5 10.8 15 0.3 32 28
CO Vinoth 23 M 566499 N N N N N N N N - - 9 96 4.6 9 33 0.8 23 28
CO Hariprasanth 27 M 56655 N N N N N N N N - - 9.2 112 4.3 9.2 18 0.9 18 28
CO Ramesh 36 M 53579 N N N N N N N N - - 9 42 4.6 9 18 0.6 18 26
CO Imthiyash 43 M 53892 N N N N N N N N - - 9.2 56 4.3 9.2 18 0.5 12 32
CO Mithuna 30 F 816443 N N N N N N N N - - 9.3 43 4.6 9.3 18 0.6 18 26
CO Balaraman 37 M 931662 N N N N N N N N - - 9.4 42 4.2 9.4 23 0.7 22 28
CO Chithra 28 F 916387 N N N N N N N N - - 9.8 136 4.4 9.8 21 0.9 21 29
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CO Aruna 20 F 316593 N N N N N N N N - - 8.8 81 4.7 8.8 25 0.6 23 31
CO Samuel 27 M 643081 N N N N N N N N - - 9.5 123 4.6 9.5 19 1 18 25
CO Sundari 40 F 913470 N N N N N N N N - - 10 110 4.9 10 26 1.4 31 21
CO Saroja 46 F 931636 N N N N N N N N - - 9.9 94 4.2 9.9 22 0.8 22 26
CO Babu 23 M 346558 N N N N N N N N - - 9.7 81 4 9.7 18 0.6 18 22
CO Babu 27 M 824859 N N N N N N N N - - 9.8 32 4.7 9.8 19 0.4 18 26
CO Kanniyammal 46 F 770891 N N N N N N N N - - 9.2 62 4.3 9.2 17 0.8 18 29
CO Dhanush 19 M 82806 N N N N N N N N - - 9.6 20 4.3 9.6 18 0.7 18 26
CO Durga 32 F 858080 N N N N N N N N - - 9.3 82 4.3 9.3 17 0.5 18 26
CO Aswin 23 M 828101 N N N N N N N N - - 8.9 46 4.5 8.9 20 1 18 29
CO Subramani 40 M 826556 N N N N N N N N - - 9.7 112 4.3 9.7 18 0.7 22 38
CO Jaya 36 F 827219 N N N N N N N N - - 8.9 98 4.5 8.9 19 0.6 16 28
CO Roja 20 F 827848 N N N N N N N N - - 8.8 78 4.3 8.8 17 0.5 18 28
CO Valli 36 F 53957 N N N N N N N N - - 10.3 122 4.7 10.3 20 0.9 18 27
CO Saravanan 35 M 821634 N N N N N N N N - - 9.6 88 4.8 9.6 22 0.5 12 28
CO Balaraman 46 M 801918 N N N N N N N N - - 8.9 92 4.7 8.9 17 0.6 22 38
CO Radha 40 F 15699 N N N N N N N N - - 9.8 62 4.8 9.8 20 0.6 18 32
CO Fathima 20 F 818771 N N N N N N N N - - 9.6 56 4.2 9.6 28 0.5 22 28
CO Mariyammal 40 F 52921 N N N N N N N N - - 9.3 72 4.3 9.3 18 0.5 18 29
CO Malar 40 F 759275 N N N N N N N N - - 8.9 92 4.8 8.9 18 0.8 22 28
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CO Divya 19 F 817179 N N N N N N N N - - 9.8 66 4.9 9.8 17 0.8 19 26
CO Manigandan 36 M 818843 N N N N N N N N - - 9.8 98 4.6 9.8 18 0.7 17 26
CO Subasri 32 F 659381 N N N N N N N N - - 9.9 67 4.8 9.9 32 1.1 19 24
CO Gopal 40 M 732681 N N N N N N N N - - 9 118 4.8 9 17 0.6 22 28
CO Komathy 35 F 820025 N N N N N N N N - - 8.9 42 4.8 8.9 16 0.8 19 32
CO Krishnan 45 M 821734 N N N N N N N N - - 9.3 36 4.3 9.3 17 0.6 16 28
CO Muthu 45 M 824184 N N N N N N N N - - 8.6 56 4.3 8.6 17 0.9 28 37
CO Seetha 27 F 822312 N N N N N N N N - - 9.3 46 4.7 9.3 18 0.9 22 16
CO Santhosh 19 M 51648 N N N N N N N N - - 10.2 96 4.3 10.2 18 0.5 26 18
CO Suriya 19 F 171232 N N N N N N N N - - 9.3 82 4.3 9.3 25 0.6 46 32
CO Rani 40 F 812205 N N N N N N N N - - 8.8 118 4.5 8.8 24 0.9 23 35
CO Chandirasekar 36 M 808728 N N N N N N N N - - 9.8 82 4.2 9.8 19 0.9 12 18
CO Raman 40 M 791196 N N N N N N N N - - 9.4 92 4.4 9.4 18 0.7 22 36
CO Perameshwari 45 F 710200 N N N N N N N N - - 9.2 110 4.4 9.2 17 0.4 32 18
CO Yasotha 34 F 162488 N N N N N N N N - - 8.9 128 4.8 8.9 16 0.4 22 36
CO Vatchala 43 F 804834 N N N N N N N N - - 10.3 84 4.9 10.3 22 0.5 18 26
CO Purusothaman 20 M 815054 N N N N N N N N - - 9.9 86 4.3 9.9 25 0.8 22 36
CO Sumathi 38 F 806112 N N N N N N N N - - 9.5 86 4.3 9.5 18 0.5 12 28
CO Ranganathan 46 M 1327636 N N N N N N N N - - 8.9 88 4.7 8.9 29 1.1 29 28
CO Jaya 32 F 191315 N N N N N N N N - - 10.3 75 4.5 10.3 27 0.4 30 24
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CO Jaruth 24 M 131614 N N N N N N N N - - 9 62 4.2 9 25 0.6 27 20
CO Pounammal 45 F 16738 N N N N N N N N - - 9.5 88 4.6 9.5 28 0.9 17 29
CO Sarath 23 M 46551 N N N N N N N N - - 9.6 82 4.6 9.6 22 0.9 12 18
CO Renuga 38 F 803849 N N N N N N N N - - 9.8 90 4.6 9.8 20 0.8 21 30
CO Alazal khan 27 M 808129 N N N N N N N N - - 9 97 4.6 9 18 0.9 13 25
CO Sumathi 38 F 880611 N N N N N N N N - - 8.9 100 4.3 8.9 18 0.7 21 28
CO Purushothmam 20 M 815054 N N N N N N N N - - 8.9 98 4.6 8.9 18 0.8 16 20
CO Uma 36 F 162488 N N N N N N N N - - 9.3 100 4.7 9.3 18 0.9 16 18
CO Parameshwari 40 F 710200 N N N N N N N N - - 9.8 102 4.7 9.8 18 0.8 16 22
CO Chandrasekar 36 M 791196 N N N N N N N N - - 8.8 98 4.8 8.8 32 0.9 21 26
CO Suresh 32 M 720916 N N N N N N N N - - 9.6 88 4.7 9.6 18 0.9 21 26
CO Kala 32 F 679011 N N N N N N N N - - 10.2 100 4.6 10.2 18 0.7 21 25
CO Najaraj 36 F 889250 N N N N N N N N - - 9.8 92 4.6 9.8 18 0.8 18 20
CO Perumal 40 M 6397 N N N N N N N N - - 9.3 40 4.7 9.3 18 0.9 21 27
CO Jayanthi 19 F 931655 N N N N N N N N - - 9.5 78 4.9 9.5 29 0.9 23 30
CO Rani 36 F 583044 N N N N N N N N - - 9.3 65 4.7 9.3 24 0.7 21 27
CO Sankari 38 F 602505 N N N N N N N N - - 9.7 57 4.5 9.7 28 0.8 25 32
CO Manimegalai 42 F 191931 N N N N N N N N - - 9.1 52 4.4 9.1 20 0.5 19 24
CO Venda 27 F 764007 N N N N N N N N - - 9.2 72 4.3 9.2 18 0.9 21 27
CO Yasotha 36 F 801179 N N N N N N N N - - 8.9 92 4.7 8.9 18 0.8 21 26
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CO Elangovan 43 M 783172 N N N N N N N N - - 8.8 120 4.6 8.8 32 0.9 18 12
CO Renuka 34 F 788716 N N N N N N N N - - 9.2 86 4.8 9.2 32 0.7 21 28
CO Prasanth 30 M 51629 N N N N N N N N - - 9.3 62 4.7 9.3 28 0.9 16 18
CO Malar 40 F 818692 N N N N N N N N - - 8.9 92 4.9 8.9 19 0.8 20 26
CO Loganathan 20 M 817211 N N N N N N N N - - 8.8 100 4.6 8.8 22 0.9 22 36
CO Jayasri 24 F 50726 N N N N N N N N - - 10.3 96 4.6 10.3 32 0.8 20 26
CO Kalairani 25 F 50422 N N N N N N N N - - 9.3 98 4.6 9.3 32 0.9 22 28
CO Rajendiran 45 M 51478 N N N N N N N N - - 9.6 102 4.3 9.6 28 0.8 20 24
CO Rani 40 F 812205 N N N N N N N N - - 9.6 90 4.6 9.6 18 0.3 18 22
CO Elumalai 38 M 802990 N N N N N N N N - - 8.6 98 4.6 8.6 18 0.9 22 26
CO Mohan 35 F 35048 N N N N N N N N - - 8.9 112 4.6 8.9 28 0.8 22 28
CO Vijaya 24 F 799341 N N N N N N N N - - 9.3 92 4.9 9.3 18 0.8 21 28
CO Mustafa 32 M 301358 N N N N N N N N - - 9.4 96 4.5 9.4 22 0.8 21 32
CO Munirathinam 35 M 876516 N N N N N N N N - - 9.6 138 4.6 9.6 20 1 16 24
CO Sathya 25 F 816527 N N N N N N N N - - 9.5 108 4.4 9.5 19 0.5 26 38
CO Uma 30 F 786924 N N N N N N N N - - 9.2 96 4.8 9.2 26 0.9 16 34
CO Arul 26 M 826595 N N N N N N N N - - 8.9 56 4.7 8.9 24 0.9 24 30
CO Sureshbabu 42 M 826597 N N N N N N N N - - 8.5 62 4.8 8.5 22 0.7 14 26
CO Balu 36 M 826609 N N N N N N N N - - 9.3 72 4.7 9.3 16 0.6 16 32
CO Chinnaponnu 36 F 826604 N N N N N N N N - - 8.7 108 4.3 8.7 19 0.7 26 32
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CO Kuppan 45 M 526596 N N N N N N N N - - 8.8 118 4.5 8.8 17 0.5 24 36
CO Parrathi 44 F 15151 N N N N N N N N - - 10.3 102 4.7 10.3 20 0.8 22 38
CO Shanmugam 30 M 82587 N N N N N N N N - - 9.6 97 4.7 9.6 21 0.8 29 34
CO Jothi 28 M 826586 N N N N N N N N - - 10.3 47 4.3 10.3 18 0.9 21 28
CO Amsa 42 F 826580 N N N N N N N N - - 9.5 89 4.7 9.5 18 0.9 16 23
CO Sandhiya 20 F 862717 N N N N N N N N - - 9.3 75 4.7 9.3 16 0.5 22 40
CO Gajalakshmi 40 F 82659 N N N N N N N N - - 8.9 128 4.3 8.9 20 0.8 18 26
CO Rajathi 40 F 826395 N N N N N N N N - - 9.5 92 4.3 9.5 17 0.9 18 26
CO Rajgopal 20 M 826326 N N N N N N N N - - 8.6 92 4.5 8.6 17 0.6 16 26
CO Kumar 36 M 526882 N N N N N N N N - - 8.8 56 4.4 8.8 24 0.8 22 28
CO Rani 46 F 15298 N N N N N N N N - - 9.2 64 4.7 9.2 20 0.8 16 32
CO Lalli 40 F 321983 N N N N N N N N - - 9.8 128 4.5 9.8 19 0.6 17 25
CO Rajakumari 30 F 873261 N N N N N N N N - - 10.5 112 4.7 10.5 17 0.9 14 26
CO Nandhini 22 F 802806 N N N N N N N N - - 9.8 96 4.6 9.8 17 0.8 18 26
CO Kalai 38 F 799948 N N N N N N N N - - 9.6 108 4.7 9.6 19 0.8 16 28
CO Ushsrani 42 F 803314 N N N N N N N N - - 9.6 62 4.4 9.6 13 0.6 14 28
CO Rangaraj 46 M 45089 N N N N N N N N - - 9.4 66 4.8 9.4 12 0.5 18 29
CO Sekar 25 M 802990 N N N N N N N N - - 9.6 107 4.7 9.6 19 0.8 18 32
CO Deva 40 M 513276 N N N N N N N N - - 9.8 96 4.6 9.8 19 0.5 16 25
CO Venkatesan 33 M 808594 N N N N N N N N - - 9.8 54 4.5 9.8 16 0.7 20 36
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CO Niranjani 28 F 811979 N N N N N N N N - - 10.4 82 4.8 10.4 17 0.5 18 26
CO Suriya 20 F 51691 N N N N N N N N - - 9 48 4.7 9 24 0.8 17 26
CO Dhanapal 45 M 51148 N N N N N N N N - - 9.8 66 4.3 9.8 17 0.8 19 28
CO Kothandam 40 M 818648 N N N N N N N N - - 8.8 74 4.8 8.8 23 0.8 26 40
CO Pandiyan 46 M 210593 N N N N N N N N - - 9.5 126 4.3 9.5 19 0.5 17 28
CO Naveendiran 19 M 827554 N N N N N N N N - - 8.2 112 4.6 8.2 19 0.7 22 28
CO Chinnathai 46 F 823548 N N N N N N N N - - 7.6 120 4.8 7.6 20 0.5 22 28
CO Nellammal 39 F 827619 N N N N N N N N - - 8.1 124 4.9 8.1 22 0.9 22 29
CO Magesh 36 M 825768 N N N N N N N N - - 8.2 146 4.7 8.2 19 1 20 29
CO Jothi 40 F 820171 N N N N N N N N - - 7.8 106 4.4 7.8 28 0.7 22 29
CO Jaya 25 F 82503 N N N N N N N N - - 8.1 96 4.6 8.1 18 0.9 22 30
CO Pomgavanam 26 F 326016 N N N N N N N N - - 8.9 98 4.6 8.9 32 0.8 16 23
CO Santhoskumar 40 M 826027 N N N N N N N N - - 8.2 42 4.6 8.2 18 0.9 16 22
CO Settu 33 M 55464 N N N N N N N N - - 6.9 49 4.6 6.9 18 0.9 18 26
CO Janaki 40 F 182767 N N N N N N N N - - 8.2 147 4.1 8.2 28 1 25 28
CO Peurumalsamy 43 M 827684 N N N N N N N N - - 8.3 166 4.6 8.3 24 0.5 19 23
CO Eswari 37 F 827685 N N N N N N N N - - 8.3 182 4.7 8.3 20 0.8 22 19
CO Isthiya 19 M 827689 N N N N N N N N - - 8 114 4.3 8 23 0.9 29 22
CO Radhabai 36 F 827609 N N N N N N N N - - 8.1 58 4.7 8.1 19 0.8 33 29
CO Venda 26 F 827700 N N N N N N N N - - 8.4 78 4.6 8.4 14 0.5 16 20
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CO Amsa 35 F 827699 N N N N N N N N - - 8.2 86 4.2 8.2 17 0.8 19 22
CO Rajasekar 46 M 82772 N N N N N N N N - - 8.1 92 4.8 8.1 20 1 22 28
CO Karan 19 M 829715 N N N N N N N N - - 8.4 106 4.5 8.4 24 0.7 26 21
CO Vasanth 28 M 327673 N N N N N N N N - - 8 153 4.3 8 16 0.7 16 22
CO Karthiya 23 F 620816 N N N N N N N N - - 9.2 148 4.6 9.2 18 0.5 23 27
CO Raman 42 M 826060 N N N N N N N N - - 8.1 105 4.9 8.1 17 0.9 26 21
CO Sridhar 32 M 826068 N N N N N N N N - - 8.3 92 4.3 8.3 20 1 18 23
CO Kuppammal 40 F 826055 N N N N N N N N - - 8.4 78 4.8 8.4 26 1 22 31
CO Maniyan 45 M 828059 N N N N N N N N - - 8.2 67 4.5 8.2 23 0.8 19 25
CO Valli 32 F 826052 N N N N N N N N - - 7.8 35 4 7.8 16 0.5 14 22
CO Sankari 32 F 826058 N N N N N N N N - - 10.5 186 4.9 10.5 20 0.4 29 17
CO Rosy 35 F 826081 N N N N N N N N - - 9.7 147 4.3 9.7 19 0.6 22 26
CO Subramani 40 M 827524 N N N N N N N N - - 8 96 4.6 8 28 0.7 20 26
CO Kali 37 M 53205 N N N N N N N N - - 9.1 56 4.6 9.1 19 0.8 18 36
CO Raj 35 M 53995 N N N N N N N N - - 8.6 193 4.6 8.6 19 0.5 22 46
CO Pughazhendi 18 M 829824 N N N N N N N N - - 8.6 199 4.2 8.6 32 0.9 36 15
CO Devan 42 M 131672 N N N N N N N N - - 10.1 149 4.8 10.1 23 0.8 25 33
CO Damodaran 39 M 826066 N N N N N N N N - - 8.7 163 4.3 8.7 20 0.4 19 23
CO Soundar 32 M 861205 N N N N N N N N - - 9.5 176 4.9 9.5 27 0.9 30 19
CO Bhuvana 35 F 865321 N N N N N N N N - - 8.8 143 4.5 8.8 30 0.6 18 27
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CO Manimagalai 42 F 826056 N N N N N N N N - - 8.9 181 4.2 8.9 23 0.8 26 19
CO Kanchana 38 F 617819 N N N N N N N N - - 9.5 165 4.5 9.5 18 0.9 20 16
CO Sukesh 19 M 602195 N N N N N N N N - - 9.6 158 4.2 9.6 24 0.7 28 18
CO Selvam 42 M 826015 N N N N N N N N - - 10.2 147 4.8 10.2 20 1 29 21
CO Gopal 42 M 610956 N N N N N N N N - - 8.8 154 4.6 8.8 28 0.9 16 25
CO Dharani 40 F 926814 N N N N N N N N - - 8 175 4.7 8 19 0.8 18 25
CO Suresh 38 M 926514 N N N N N N N N - - 8.3 156 4.3 8.3 16 0.5 21 30
CO Narayanasami 40 M 826051 N N N N N N N N - - 7.9 46 4.3 7.9 18 0.5 17 21
CO Vijayan 35 M 827716 N N N N N N N N - - 8.3 53 4.8 8.3 22 0.6 27 21
CO Mariya 19 F 827782 N N N N N N N N - - 8 86 4.6 8 28 0.3 16 21
CO Nivedha 20 F 826046 N N N N N N N N - - 8.4 115 4.3 8.4 22 0.4 23 30
CO Sajitha 21 F 826082 N N N N N N N N - - 8 109 4 8 27 0.8 18 24
CO Muneeswaran 44 M 826053 N N N N N N N N - - 8.2 93 4.9 8.2 30 1 20 26
CO Dharman 47 M 826058 N N N N N N N N - - 8.3 75 4.6 8.3 21 0.6 24 18
CO Venkateswaran 43 M 826052 N N N N N N N N - - 8.1 62 4.7 8.1 23 .0.9 21 25
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KEY TO MASTER CHART:
C – case
CO – control
Neck Sx – Neck Surgery
Pst Ac. Abd – Past Acute Abdomen
RAD – Radiation
HT – Hypertension
DM – Diabetes Mellitus
Alc – Alcohol
SD – Seizure Disorder
DUR – Duration
P – Phenytoin
PB – Phenobarbitone
CB – Carbamazepine
SV – Sodium Valproate
Ca – Calcium
ALP – Alkaline Phosphatase
Alb – Albumin
Co. Ca – Corrected Calcium
Cr – Creatinine
SGOT – Serum glutamic oxaloacetic transaminase
SGPT – Serum glutamic pyruvic transaminase
M – Male
F – Female
Y – Yes
N – NO
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PATIENT CONSENT FORM
STUDY DETAIL: “A  STUDY ON PREVALENCE OF MICROALBUMINURIA IN NON-
DIABETIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN
ICCU IN GOVERNMENT VELLORE MEDICAL COLLEGE HOSPITAL,
VELLORE”
STUDY CENTRE:
PATIENT’S NAME:
PATIENT’S AGE:
IDENTIFICATION NUMBER:
I confirm that I have understood the purpose and procedure of the above study.
I have the opportunity to ask questions and all my questions and doubts have been
answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I am free to
withdraw at any time without giving reason, without my legal rights being affected.
I understand that the sponsor of the clinical study, others working on the
sponsor’s behalf, the ethical committee and the regulatory authorities will not need my
permission to look at my health records, both in respect of the current study and any
further research that may be conducted in relation to it, even if I withdraw from the
study I agree to this access. However I understand that my identity would not be
revealed in any information released to third parties or published, unless as required
under the law. I agree not to restrict the use of any data or results that arise from this
study.
I hereby consent to participate in this study.
I hereby give permission to undergo complete clinical examination and
diagnostic tests including haematological, biochemical, radiological tests.
Signature/thumb impression:
Patient’s name and address:                                             Place:                              Date:
Signature of the investigator:
Name of the investigator: Place:                              Date
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